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Part I: Protective Mucosal Immunology Mediated by Epithelial CD1d and 
IL-10 
1 Introduction 
1.1 Inflammatory Bowel Disease 
Inflammatory Bowel Disease (IBD) is a collective term for chronic remittent or 
progressive inflammatory disorders of the intestine. There are two major forms of 
IBD. Crohn’s Disease (CD) can affect the entire gastrointestinal tract, but most 
commonly involves the small intestine and the colon. It is characterized by transmural 
inflammation that usually occurs in patches and is sometimes associated with fistulas 
or granulomas. Ulcerative colitis (UC) is limited to the rectum and colon and is 
characterized by inflammation of the superficial colonic mucosa. Though there are 
familial cases of IBD, intestinal inflammation most commonly occurs sporadically. 
Further, both forms are associated with an increased risk for intestinal or colorectal 
cancer.1–3 While the precise mechanisms behind the development of IBD remain 
widely elusive, three essential components have been identified: the homeostasis of 
the intestinal immune system, host-microbe interactions and genetic factors.1  
A common hypothesis for the development of IBD is that environmental stimuli 
induce uncontrolled intestinal inflammation in genetically susceptible individuals.1 The 
human intestinal tract houses a multitude of commensal bacteria that co-exist with 
the host’s immune system in a mutually beneficial relationship.4 In patients with IBD, 
the immune system shows an inadequate, excessive response, which is in part 
directed against the commensal microbiota and is associated with severe intestinal 
inflammation.1–3 While both the innate and adaptive immune system contribute to the 
pathogenesis of IBD, recent data suggest a critical involvement of CD1d-restricted, 
lipid-reactive Natural Killer T (NKT) cells in the initiation and promotion of intestinal 
inflammation in human UC.5,6  
1.2 Natural Killer T cells and Their Role in Intestinal Homeostasis 
NKT cells are a subset of T cells that were originally characterized by the co-
expression of an αβ T cell receptor (TCR) and the NK cell marker NK1.1.7 This 
definition has since been redefined to describe lipid-reactive T cells that are restricted 
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by the atypical major histocompatibility complex (MHC) class I molecule CD1d 
(cluster of differentiation 1 d).8  
NKT cell development begins in the thymus with a double negative (DN) stage, which 
develops into a CD4+CD8+ double positive (DP) stage upon expression of the TCR. 
During this DP stage, NKT cells undergo positive selection upon interaction with 
CD1d molecules loaded with endogenous, agonistic lipid antigens, expressed on 
other DP thymocytes. The lipid antigens involved in this positive selection remain to 
be identified. Unlike conventional T cells, NKT cells undergo multiple rounds of 
expansion in the thymus, during which they develop an effector/memory phenotype, 
before emigrating to the periphery.9–11  
There are two subsets of NKT cells: Type I NKT cells, or invariant NKT (iNKT) cells, 
use a limited set of TCR genes to form a semi-invariant TCR. In mice, this TCR is 
composed of a Vα14-Jα18 α-chain, preferentially combined with a Vβ8.2, Vβ7 or Vβ2 
β-chain. Human iNKT cells express a TCR consisting of a Vα24J-α18 α-chain, which 
preferentially assembles with a Vβ11 β-chain. Type II NKT cells, or non-invariant 
NKT (niNKT) cells, have a broader TCR repertoire and are less well understood 
compared to iNKT cells. Despite the limited variability of the iNKT TCR, iNKT cells 
are capable of detecting a range of lipids presented by CD1d.12 One of the most 
agonistic lipids identified to date is α-galactosylceramide (αGalCer), which was 
originally isolated from a marine sponge.13 The use of CD1d tetramers loaded with 
αGalCer allows for the highly specific detection of iNKT cells8,10,14 In contrast, a 
specific and universal method for the detection of niNKT cells has not been described 
so far, although a subset of niNKT cells can be successfully detected using 
sulfatide-loaded CD1d tetramers.15  
Due to their versatility, iNKT cells have been named a “Swiss Army Knife” by 
Matsuda and colleagues.11 By rapid secretion of copious amounts of various 
cytokines and chemokines, iNKT cells act on many other cells of the innate and 
adaptive immune system, thereby acting as an important mediator between innate 
and adaptive immunity (Figure 1).9 As such, they are involved in a multitude of 
immune responses, including bacterial, parasitic and viral clearance, allergies, anti-
tumor responses and inflammatory conditions.12 Most NKT cells express surface 
antigens reflective of their status as effector memory T cells. One of the most 
characteristic features of iNKT cells is their capacity to secrete large amounts of IL-4 
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and IFNγ only hours after activation, thereby diverting the immune reaction either 
towards a Th1 or a Th2 response.11  
 
Figure 1: NKT Cells Secrete Various Cytokines Upon Activation 
A CD1d molecule expressed on an antigen presenting cell (APC) loaded with a lipid antigen 
interacts with the NKT TCR, activating the NKT cell. NKT cells are capable of producing a 
range of cytokines and thereby influence most cells of the innate (left) and adaptive (right) 
immune system. Adapted from Matsuda et al. 2008.11 
Studies investigating the relative frequencies of NKT cells in the intestines of 
mice8,16,17 and humans5,18 did not lead to conclusive results, most likely because the 
accuracy of the methods used for the detection of NKT cells varies greatly. Within 
older studies, NKT cells were identified based on the historic definition of 
CD3+/TCRαβ+NK1.1+ cells, the more precise αGalCer-loaded CD1d tetramer has 
become the method of choice in more recent studies. It did become apparent, 
though, that iNKT cells only make up for a small fraction of lamina propria 
lymphocytes (LPL) and intraepithelial lymphocytes (IEL) (max. 0.5 % of LPLs in 
studies using the αGalCer-loaded CD1d tetramer).5,17 Nevertheless, this small subset 
of immune cells has a significant impact on the severity of intestinal inflammation in 
various animal models of IBD. Oxazolone colitis, a mouse model of UC induced by 
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rectal administration of the haptenating agent oxazolone, has been shown to be 
strongly dependent on secretion of Th2 cytokines (IL-4 and IL-13) from iNKT 
cells.5,16,19 Jα18-/- mice, which do not express the canonical iNKT TCR and therefore 
do not develop iNKT cells, as well as CD1d-/- mice, which are devoid of all NKT cells 
due to impaired CD1d-restricted positive selection in the thymus, do not develop 
oxazolone colitis.5,16,20 Studies in human UC patients also revealed CD1d-dependent 
secretion of epithelial barrier-disruptive IL-13, associated with NKT cell-dependent 
immune responses. However, contrary to observations made in mice, the T cells 
involved in the secretion of IL-13 did not bind the αGalCer-loaded CD1d tetramer and 
were therefore likely niNKT cells and not iNKT cells.5,6  
Conversely, αGalCer-primed iNKT cells have been shown to ameliorate intestinal 
inflammation in Th1 driven mouse models of intestinal inflammation, such as DSS 
colitis, which is less dependent on the adaptive immune response than oxazolone 
colitis.21,22 The most likely explanation for this observation is that NKT cells 
stimulated with αGalCer robustly secrete Th2 cytokines, such as IL-4, and thereby 
counteract the Th1 response causing the inflammation.23 
How an NKT cell reacts to antigen presentation likely depends on the lipid antigen 
presented and the APCs involved in this process. Since CD1d is widely expressed by 
a range of cell types, antigens are not only presented by professional APCs such as 
dendritic cells, but also by endothelial or epithelial cells.24 For a long time, the 
intestinal epithelium was seen as a solely physical barrier between the microbiota 
and the intestinal immune system. However, it has become apparent that intestinal 
epithelial cells (IECs) can actively influence intestinal homeostasis through secretion 
of cytokines under constitutive conditions and upon exposure to parasites, bacteria or 
pro-inflammatory cytokines.25 Moreover, malfunctions in IEC physiology, for instance 
through excessive ER stress responses, can cause spontaneous intestinal 
inflammation.1,26 Crosslinking experiments of CD1d on intestinal epithelial cell lines in 
vitro have demonstrated the induction of heat shock protein 110 (HSP110) and IL-10 
upon engagement of CD1d.27,28 Both of these proteins may have a beneficial effect 
on intestinal inflammation, if engagement of CD1d on IECs also induces their 
expression in vivo. This raised the question of whether CD1d-mediated antigen 
presentation by IECs and subsequent activation of intestinal NKT cells might have a 
different effect on intestinal homeostasis compared to antigen presentation by 
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professional antigen presenting cells. Indeed, we could demonstrate in collaboration 
with Dr. Richard S. Blumberg’s laboratory that the response of NKT cells to antigen 
presentation does not only depend on the antigen itself, but also on the antigen 
presenting cell. As such, antigen presentation by the intestinal epithelium induces a 
protective immune response, rather than an inflammatory response, while bone 
marrow-derived immune cells contribute to the pathogenesis of intestinal 
inflammation in a CD1d-restricted manner.29 This demonstrates that lipid antigen 
presentation plays critical roles in NKT cell immunity and promotes beneficial as well 
as pathogenic NKT cell-dependent immune responses in mucosal immunity.  
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3 Discussion 
In this study we could reveal an epithelial signaling pathway critical for intestinal 
homeostasis, involving intestinal epithelial CD1d, HSP110 and IL-10. To this end we 
show that mice with impaired CD1d-mediated antigen presentation by IECs 
(Cd1d1ΔIEC, MttpΔIEC mice) were significantly more susceptible to oxazolone colitis 
than WT mice, which was due to impaired epithelial expression of HSP110 and IL-10. 
It was previously demonstrated that epithelial CD1d can promote the production of 
IL-10.27 This study further suggested that CD1d-dependent expression and secretion 
of IL-10 is dependent on retrograde signaling of CD1d through its cytoplasmic tail. 26 
To test whether similar principles apply to IECs in vivo, we performed cross-linking 
experiments on purified IECs from mice expressing “tail-deleted” CD1d, lacking the 
intracellular C-terminus of CD1d (TD-CD1d). Indeed, IECs obtained from these mice 
exhibited reduced expression of Hsph1 and Il10 mRNA under constitutive conditions 
and also after sensitization of the mice with the iNKT cell agonist αGalCer, thus 
supporting the notion that retrograde CD1d signaling promotes the expression of 
IL-10 by IECs. STAT3, which can bind to STAT sites in the promoters of the Cd1d1, 
Hsph1 and Il10 genes, was identified as potential downstream target of CD1d. 30 
siRNA-mediated knockdown of Stat3 in an intestinal epithelial cell line indeed 
resulted in reduced transcription of Cd1d1, Hsph1 and Il10 mRNA. Additionally, 
reduced STAT3 phosphorylation was observed in IECs of Cd1d1ΔIEC and TD-Cd1d 
mice, confirming its role as integrating factor in the described protective CD1d-
dependent signaling pathway in IECs. These results are in accordance with 
preceding studies demonstrating the importance of the activation of intestinal 
epithelial STAT3 in the regulation of intestinal homeostasis and wound healing during 
colitis.31,32 Interestingly, IL-10 and HSP110 themselves can signal through STAT3 
and thereby further increase their own expression, along with that of CD1d, thus 
generating a positive feedback loop.  
However, constantly activated STAT3 is also involved in the development of 
colorectal cancer and acts downstream of IL-6 and IL-11 signaling during chronic 
inflammation.33,34 It is therefore possible, that the described feedback loop, while 
protecting from acute intestinal inflammation, may promote the development of 
colorectal cancer.35 This needs to be investigated further, as does the exact 
mechanism behind retrograde CD1d signaling. Nevertheless, our studies clearly 
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demonstrate the importance of IEC-derived IL-10 downstream of STAT3 in the 
amelioration of intestinal inflammation.  
Another interesting aspect which was not explored during the course of these studies 
is the repertoire of lipids associated with intestinal epithelial CD1d and their effect on 
retrograde CD1d signaling. CD1d is capable of binding a range of endogenous lipid 
species, including phospholipids and glycosphingolipids, of which only few have been 
identified as NKT cell antigens.12,36–41 Multiple studies have established that 
inflammatory responses can affect cellular lipid metabolism and thus CD1d-mediated 
antigen presentation.12 Also, a recent publication by Iyer et al. established that 
STAT3 is involved in the expression of an enzyme required for the biosynthesis of 
glycosphingolipids. STAT3-deficient APCs exhibited reduced presentation of 
endogenous antigens to NKT cells, while the presentation of exogenous antigens 
was not impaired.42 With respect to our study this may suggest that epithelial lipid 
metabolism - and thus potentially CD1d-mediated antigen presentation to NKT cells - 
may not only be influenced by the inflammatory conditions in the intestine during 
colitis, but also by STAT3-dependent processes upon retrograde CD1d signaling.  
However, the investigation of CD1d-associated lipids is laborious and has been of 
limited success because classical protein isolation methods involving detergents 
cannot be utilized for the isolation of CD1d-lipid complexes. We thus set out to 
establish genetically engineered CD1d proteins, which can be enzymatically cleaved 
from the cell surface of eukaryotic cells instead of requiring extraction from the 
plasma membrane (Part II). Cell-surface cleavable CD1d proteins would be an 
invaluable asset for the investigation of CD1d-associated lipids in vitro and in vivo 
and would help to address the question of whether cell-intrinsic differences in the 
CD1d-associated lipid repertoire provide the basis for APC-specific effects of CD1d in 
intestinal inflammation.  
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Part II: Genetically Engineered CD1d Proteins for the Investigation of the 
CD1d-Associated Lipid Repertoire 
1 Introduction 
1.1 CD1d Structure and Trafficking  
CD1d is a member of the CD1 (cluster of differentiation 1) family of proteins, which is 
separated into group 1 (CD1a, CD1b, CD1c) and group 2 (CD1d). Since group 1 
CD1 proteins are not expressed by mice, CD1d is the most extensively researched 
CD1 protein.12,43 By presenting antigens to lipid-reactive T cells, such as NKT cells, 
CD1 proteins play important roles in immune homeostasis.  
CD1 proteins are structurally similar to classical MHC class I proteins, bearing three 
N-terminal extracellular domains (α1-3), a single transmembrane domain (TMD) and 
an intracellular C-terminal domain. However, unlike classical MHC class I and II 
molecules, CD1 family members do not bind peptide antigens, but lipids.44 This can 
be attributed to deeper, largely hydrophobic antigen binding pockets (A’ and 
F’ pockets and additional C’ and T’ pockets in CD1b). These accommodate the fatty 
acyl tails of the lipids and leave the headgroups accessible for presentation to 
CD1-restricted T cells.43 Antigen-binding groove volumes vary between the CD1 
isoforms, allowing for presentation of distinct lipid antigens by different molecules 
(Figure 2).45  
 
Figure 2: Schematic Depiction of the Antigen-Binding Grooves of the CD1 Isoforms 
CD1a, c and d have two antigen-binding pockets (A’ and F’) , while CD1b has two 
additional loops (C’ and T’). Adapted from De Libero and Mori, 2010 46. 
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CD1d synthesis depends on ER chaperones such as calnexin, calreticulin and the 
thiol oxidoreductase ERp57, which support correct folding and disulfide bond 
formation of the CD1d heavy chain. Once CD1d is in its correct conformation, it 
leaves the ER as a free heavy chain or as a heterodimer,  non-covalently associated 
with β2-microglobulin (β2m) at the α3 domain.
44,47,48 CD1d passages along the 
secretory pathway and is believed to load lipids in each of the compartments: from 
the ER through the Golgi complex to the plasma membrane, where it presents lipid 
antigens to CD1d-restricted NKT cells.43 Continuing on from the plasma membrane, 
human (h) and mouse (m) CD1d undergo different internalization pathways. While 
hCD1d only passes through early endosomes and the endocytic recycling 
compartment, mCD1d additionally passes through late endosomes and lysosomes 
before recycling back to the plasma membrane.45 Internalization of human and 
mouse CD1d is clathrin-dependent and is mediated by interaction of adaptor proteins 
(AP) with a tyrosine-based sorting motif (YXXϕ) in the cytoplasmic tail of the CD1d 
heavy chain. This sequence of two random amino acids (X) which are framed by a 
tyrosine (Y) and a bulky hydrophobic amino acid (ϕ) binds to the µ domain of AP2, 
mediating entry into early endosomes. 49–52 The mCD1d YXXϕ motif additionally 
associates with the µ3A subunit of AP3, which targets the protein to lysosomes 
(Figure 3).43,53  
1.2 CD1d-Associated Lipids 
Different studies have demonstrated that defects in the trafficking of and lipid transfer 
onto CD1d influence its antigen presentation and thereby the development and 
function of NKT cells.52–56 While passaging through the cell, CD1d loads and 
exchanges a range of self- and non-self-lipids. Lipid loading onto CD1d in the ER is 
facilitated by lipid transfer proteins, such as the microsomal triglyceride transfer 
protein (MTP). It is believed that MTP-mediated ligand binding stabilizes the CD1d 
heavy chain before its departure from the ER.57–59 En route through the secretory 
pathway, CD1d mainly loads glycosphingolipids (GSLs), glycerophospholipids 
(GPLs) and sphingolipids, which are presented to CD1d-restricted T cells at the cell 
surface.60–62 Within the endolysosomal compartments, these lipids are exchanged for 
other endogenous or exogenous lipids (of microbial or environmental origin). This 
exchange is mediated by low pH values, which stabilize the conformation of CD1d.59 
Also, endolysosomal lipid transfer proteins, such as members of the saposin family, 
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extract lipids from membranes and load them onto CD1d in a manner not fully 
understood.51,56,63,64 These newly loaded lipids have often been previously altered by 
endolysosomal glycosidases and lipases, which process the complex glycolipid 
headgroups and lipid tails, respectively, thereby modifying lipid antigenicity.37,56,65,66 
Recycling of CD1d through the endolysosomal compartments allows the presentation 
of different lipids by the same CD1d molecule (Figure 3). 
 
Figure 3: Trafficking of mCD1d  
CD1d is synthesized in the ER of the antigen presenting cell (APC), where it is 
folded under the influence of the ER chaperones calnexin, calreticulin and 
ERp57. β2m loosely associates with the CD1d heavy chain and endogenous lipid 
is transferred onto CD1d by microsomal triglyceride transfer protein (MTP). 
Following trafficking through the Golgi apparatus and presentation of 
endogenous lipids at the cell surface, CD1d is endocytosed in a clathrin -
dependent fashion. Adaptor protein (AP)  2 mediates the transfer of CD1d into 
sorting endosomes, from where AP3 recruits CD1d into lysosomes. Endogenous 
lipids are exchanged for other endogenous or foreign antigens by means of lipid 
transfer proteins, such as saposins. Endogenous lipids are often modified by 
lysosomal enzymes such as glycosidases or lipases, CD1d is recycled to the cell 
membrane, where it presents the antigens loaded in lysosomes to CD1d-
restricted NKT cells.  
Experiments using modified CD1d molecules, which are either retained in the ER 
(ER-CD1d), secreted at the plasma membrane (secreted CD1d) or undergo normal 
trafficking though the endolysosomal compartments, revealed trafficking-dependent 
differences in the spectrum of CD1d-associated lipids. For instance, ER-retained 
CD1d mostly bound GPLs, while lipid extractions from CD1d molecules which had 
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passed through the ER and Golgi contained GPLs, GSLs and sphingolipids.60–62,67 
The majority of self-lipids associated with CD1d most likely exhibit limited to no 
antigenicity.36,37,41,68 However, some bona fide self-derived iNKT antigens have been 
identified, including glycosphingolipids such as isoglobotrihexosylceramide (iGb3), 
and phospholipids such as lysophosphatidylcholine (LPC), plasmalogen 
lysophosphatidylethanolamine (pLPE) or ether bonded lysophosphatidic acid (eLPA). 
Antigens for niNKT cells include (lyso)sulfatide and LPE, which are also antigens for 
iNKT cells (Figure 4).12,36–39,41,56 Previously, the GSLs β-galactosylceramide 
(βGalCer) and β-glucosylceramide (βGlcCer) were believed to be antigens for iNKT 
cells. 68 However, recent studies have suggested that mammalian cells may also 
produce small quantities of α-linked glucosylceramides, which cannot be 
differentiated from β-linked glucosylceramides through conventional lipidomics 
analysis. These recent studies propose that the antigenic lipids previously identified 
as βGalCer and βGlcCer are actually mammalian αGalCer and αGlcCer (Figure 
4).69,70 Microbes and inflammatory responses can influence the cellular lipid 
metabolism, thereby altering the ratio of antigenic to non-antigenic self-lipids and 
thus increasing the likelihood of NKT cell activation.12,37,60,71,72  
 
Figure 4: Antigenic Self-Lipids 
Examples of known (solid frame) and putative (dashed frame) self-lipid antigens 
for invariant and/or non-invariant NKT cells. Adapted from Dowds, Kornell, 
Blumberg, Zeissig; 2014.12 
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The range of exogenous CD1d-associated lipids is even broader. NKT cell-activating 
lipids include α-linked GSLs, phospholipids, glycolipids and lipophosphoglycans 
derived from various bacteria and protozoans. These lipids either associate with 
CD1d at the cell surface or during recycling through the endolysosomal 
compartment.12,73–77  
Considering the dimension of lipids generated and modified by eukaryotic and 
prokaryotic cells, which could theoretically be bound and presented by CD1d, this 
small number of identified lipids is likely a minor part of the complete spectrum of 
CD1d-associated lipids. Identifying NKT-activating lipids and understanding their 
origin therefore remains an important, but technically challenging, aspect of 
immunological research. 
1.3 Constructs for the Analysis of the CD1d-associated Lipidome 
Different research groups have generated modified CD1d molecules to investigate 
the CD1d-associated lipid repertoire. Adding retention signals such as a KDEL 
sequence (ER-CD1d), deleting the transmembrane and C-terminal domain (secreted 
CD1d) or deleting the last seven amino acids required for CD1d endocytosis (TD-
CD1d) have provided insight into the significance of different cellular compartments 
for CD1d and NKT cell physiology.52,53,60–62,78  
To fully characterize the CD1d-associated lipidome and thus its role in NKT cell 
physiology, it would be crucial to investigate wild type (WT) CD1d, which undergoes 
trafficking through the secretory pathway and the endolysosomal compartments. 
However, this is associated with technical difficulties, as chemical (detergents) or 
physical (freeze-thaw cycles) methods used for the isolation of transmembrane 
proteins, such as CD1d, are associated with the dissociation of lipids bound by the 
protein. A promising alternative was presented by Yuan and colleagues, as well as 
by Muindi and colleagues, who developed enzymatically cleavable CD1d constructs, 
which undergo trafficking through the secretory pathway and endolysosomal 
compartments.60,61 Both groups inserted a short peptide sequence between the TMD 
and the α3 domain of the CD1d heavy chain. One peptide sequence was the 
cleavage site associated with premature γ-IFN-inducible lysosomal thioreductase 
(GILT), which is proteolytically cleaved into its mature form in lysosomes. Yuan and 
colleagues anticipated that endogenous lysosomal cleavage of their engineered 
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CD1d protein would result in spontaneous release of CD1d once it reached the 
lysosome. However, cleavage was inefficient and the concentration of released 
CD1d therefore too low for mass spectrometry (MS)-based analysis of CD1d-
associated lipids.61  
Another strategy investigated was based on tobacco etch virus (TEV) protease.60,79 
Due to its high sequence specificity, TEV protease is commonly used for controlled 
intracellular proteolysis of fusion proteins in prokaryotic cells or cleavage of purified 
fusion proteins.80,81 Large quantities of the enzyme can be generated through 
transformation of yeast or E. coli strains with TEV protease expression plasmids, 
making it an attractive tool in biotechnology. Moreover, mutated, more stable forms of 
the protease are commercially available from different vendors.82 Muindi and 
colleagues therefore engineered a CD1d protein containing two TEV protease 
recognition sites in the juxtamembrane part of the extracellular domain of CD1d. 
However, the authors observed limited to no TEV-induced cleavage of CD1d, while 
spontaneous release of CD1d was observed. They were able to analyze glycans 
bound to the cleavable CD1d, but noted that the quantity was lower than that of 
secreted CD1d and thus information about rare lipid species may have been lost.60 
Thus, CD1d constructs which undergo unimpaired subcellular trafficking and can be 
proteolytically released at the cell surface in quantities sufficient for MS analysis do 
not exist at present.  
An interesting alternative for TEV protease might be sortase A (SrtA), a bacterial 
transpeptidase involved in the anchoring of bacterial cell wall proteins.83,84 
SrtA-mediated cleavage occurs in two sequential reactions. First, SrtA cleaves the 
threonine-glycine bond of an LPXTG sequence, forming an acyl-enzyme 
intermediate. This intermediate can then be attacked by a substrate containing an 
N-terminal amino group, which is subsequently linked to the C-terminal threonine, 
generating a fusion protein (Figure 5). Researchers have used this strategy to label 
proteins with fluorophores or affinity tags such as biotin or streptavidin.85–87 If no 
nucleophilic substrate is available, the protein can be released from the enzyme 
complex by spontaneous hydrolysis. Hence, SrtA could be used as an alternative for 
TEV protease for proteolytic release of CD1d from the plasma membrane (Figure 5).  
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Figure 5: Schematic Depiction of TEV Protease- and Sortase A-Mediated Protein 
Cleavage 
TEV protease recognizes the amino acid motif ENLYFQG and cleaves the 
peptide bond between threonine and glycine, thereby releasing the extracellular 
domain of the transmembrane protein. Sortase A transpeptidase recognizes an 
LPXTG amino acid motif, cleaves the peptide bond between threonine and 
glycine and then forms an acyl-enzyme intermediate. This intermediate can be 
attacked by a nucleophilic molecule containing an N-terminal amino group, which 
is then linked to the C-terminal threonine, resulting in release of the fusion 
protein from the enzyme.  
CD1d constructs amenable to proteolytic release at the cell surface may provide a 
critical, novel approach to the study of CD1d-associated lipids. These constructs 
would enable the analysis of lipids bound to a fully functional CD1d protein with 
unimpaired subcellular trafficking, which could be released at a given time using 
specific enzymes in the absence of detergents. Such CD1d constructs, once 
established, could be used for a range of experiments, both in vitro and in vivo. 
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Besides experiments with cultured cells, integrating these constructs into the genome 
of model organisms would allow for the investigation of spatial and temporal 
variations, as well as tissue- and disease-specific changes in the spectrum of CD1d-
associated lipids. Such strategies would provide unique insight into the lipid antigens 
involved in protective and pathogenic NKT cell responses and may provide the basis 
for future therapeutic approaches targeting NKT cells in human disease. Therefore, 
we aimed to establish engineered CD1d molecules, which are susceptible to specific 
proteolytic release at the cell surface and display unimpaired trafficking, lipid loading 
and antigen presentation. 
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2 Materials 
2.1 Antibodies  
Table 1: Antibodies 

































DH5α Chemically Competent E. coli  New England Biolabs, Frankfurt am 
Main, Germany 
Top10 Chemically Competent E. coli New England Biolabs, Frankfurt am 
Main, Germany 
2.3 Buffers and Solutions 
DMEM complete     500 ml DMEM 
       10 % FCS (v/v) 
       2 mM L-glutamine 
       1 % penicillin-streptomycin (v/v) 
 
10 x DNA Loading Dye    12.5 ml Ficoll 
       37.5 ml TE Buffer 
       25 mg Bromophenol blue 
 
ELISA Blocking Buffer    1 x PBS 
       10 % FCS (v/v) 
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ELISA Washing Buffer    1 x PBS 
       0.05 % Tween20 (v/v) 
 
FACS Buffer      1 x PBS 
       1 % FCS (v/v) 
 
10 x Hank’s Buffered Saline Solution   1.37 M NaCl 
(HBSS)      54 mM KCl 
       4.4 mM KH2PO4 
       55 mM Glucose 
       3.4 mM Na2HPO4 anhydrous 
 
       Add 4.2 mM NaHCO3 to 1 x HBSS 
 
Luria-Bertani (LB) Medium    5 g yeast extract 
       10 g bacterial peptone 
       5 g NaCl 
       H2O ad 1 l 
 
LB Agar      5 g yeast extract 
       10 g bacterial peptone 
       5 g NaCl 
       15 g Agar-Agar 
       H2O ad 1 l 
 
10 x Phosphate Buffered Saline (PBS)  1.37 M NaCl 
       27 mM KCl 
       100 mM Na2HPO4 
       18 mM KH2PO4 
 
       set pH to 7.4 
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RPMI 1640 complete    500 ml RPMI 1640  
       10 % FCS (v/v) 
       2 mM L-glutamine 
       1 % penicillin-streptomycin (v/v) 
 
50 x Tris-Acetate-EDTA (TAE) Buffer  1 M Tris base 
       0.54 % glacial acetic acid (v/v) 
       10 % EDTA 0.5 M (v/v) 
 
Tris-EDTA (TE) Buffer    10 mM Tris-HCl pH 7.5 
       1 mM EDTA 
 
2.4 Cell Lines 
24.7 cells J. Gumperz, 2000 78 
HeLa cells G.O. Gey, 1952 88 
L-cells K.K. Sanford, 1948 89 
MODE-K cells K. Vidal, 1993 90 
THP-1_hCD1d_LPETG(GGGS)3 cells Kind gift from Gijs Grotenbreg, 
Singapore, Singapore 91 
 
2.5 Cell Culture Reagents  
Dulbecco’s Modified Eagle Medium (DMEM) Biochrom, Berlin, Germany 
Fetal calf serum Biochrom, Berlin, Germany 
L-glutamine Biochrom, Berlin, Germany 
Lipofectamine 2000 Life Technologies, Darmstadt, 
Germany 
Penicillin/streptomycin solution Biochrom, Berlin, Germany 
RPMI 1640 Biochrom, Berlin, Germany 
10 x Trypsin-EDTA Solution Biochrom, Berlin, Germany 
TurboFect Life Technologies, Darmstadt, 
Germany 
Ultra-Pure water Biochrom, Berlin, Germany 
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2.6 Chemicals and Reagents 
2-Propanol Carl Roth, Karlsruhe, Germany 
Agar-Agar Carl Roth, Karlsruhe, Germany 
Agarose Carl Roth, Karlsruhe, Germany 
Ammonium chloride (NH4Cl) Merck, Darmstadt, Germany 
Ampicillin sodium salt Sigma Aldrich, Seelze, Germany 
Bacterial peptone BD Biosciences, Heidelberg, 
Germany 
BD Via-Probe Cell Viability Dye BD Biosciences, Heidelberg, 
Germany 
Bovine serum albumin (BSA) Serva, Heidelberg, Germany 
Brefeldin A Bio-Rad, München, Germany 
Bromophenol blue Sigma Aldrich, Seelze, Germany 
Disodium phosphate (Na2HPO4) Merck, Darmstadt, Germany 
EDTA 0,5 M solution pH 8.0 Applied Biosystems, Darmstadt, 
Germany 
Ethanol 99 % p.A. Carl Roth, Karlsruhe, Germany 
Ethidium bromide solution Bio-Rad, München, Germany 
Fixable Viability Dye eFluor®450 eBioscience, Frankfurt am Main, 
Germany 
Geneticin G418 sodium salt Life Technologies, Darmstadt, 
Germany 
Glucose Merck, Darmstadt, Germany 
HEPES Sigma Aldrich, Seelze, Germany 
HPLC grade water Sigma Aldrich, Seelze, Germany 
1 N Hydrochloric acid (HCl) Merck, Darmstadt, Germany 
Potassium chloride (KCl) Merck, Darmstadt, Germany 
Potassium dihydrogen orthophosphate 
(KH2PO4) 
Merck, Darmstadt, Germany 
Sodium chloride (NaCl) Carl Roth, Karlsruhe, Germany 
Sodium hydrogen carbonate (NaHCO3) Merck, Darmstadt, Germany 
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Tris base Calbiochem (Merck), Darmstadt, 
Germany 
Tris Calbiochem (Merck), Darmstadt, 
Germany 
Tween 20 Merck, Darmstadt, Germany 
Yeast extract BD Difco, Heidelberg, Germany 
  
2.7 Consumables 
6-well cell culture dish NUNC, Thermo Scientific, 
Wiesbaden, Germany 
8-well RT-PCR strips Brand, Wertheim, Germany 
96-well flat bottom cell culture dish NUNC, Thermo Scientific, 
Wiesbaden, Germany 
Biosphere® stuffed pipet tips 200 µl Sarstedt, Nümbrecht, Germany 
Centrifuge tubes 15 ml, 50 ml Sarstedt, Nümbrecht, Germany 
Combitips Advanced® 2.5 ml, 5 ml, 10 ml Eppendorf, Hamburg, Germany 
Cryopure 1 ml cryo tube Sarstedt, Nümbrecht, Germany 
Feather disposable scalpel pmf Medical, Köln, Germany 
Flow cytometry tubes, 5 ml Sarstedt, Nümbrecht, Germany 
Kimwipes Kimberly-Clark, Koblenz, Germany 
Nalgene™ Rapid-Flow™ Bottle-Top Filter 
0.22 µm 
Thermo Scientific, Schwerte, 
Germany 
Nitra-Tex® MicroTouch® gloves Ansell, Munich, Germany 
Parafilm® Brand, Wertheim, Germany 
Pasteur pipettes 230 mm Hecht-Assistent, Sondheim, 
Germany 
Peha-soft® powder free gloves Hartmann, Heidenheim, Germany 
Petri dish, 92x16 mm Sarstedt, Nümbrecht, Germany 
Pipet tips, 10 µl, 200 µl, 1000 µl, gel loader Sarstedt, Nümbrecht, Germany 
Reaction tubes 1.5 ml, 2 ml, 15 ml, 50 ml Sarstedt, Nümbrecht, Germany 
Serological pipet 5 ml, 10 ml, 25 ml Sarstedt, Nümbrecht, Germany 
T25 cm2, T75 cm2 cell culture flask Sarstedt, Nümbrecht, Germany 
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2.8 Enzymes and Substrates 
AcTEV protease and buffer Life Technologies, Darmstadt, 
Germany 
Avidin-horseradish peroxidase (HRP) Bio-Rad, München, Germany 
BamHI New England Biolabs,  
Frankfurt am Main, Germany 
dNTPs New England Biolabs,  
Frankfurt am Main, Germany 
DpnI New England Biolabs,  
Frankfurt am Main, Germany 
NheI New England Biolabs, 
Frankfurt am Main, Germany 
KpnI New England Biolabs, 
Frankfurt am Main, Germany 
ProTEV protease and buffer Promega, Mannheim, Germany 
Sortase A 121 Bio, Cambridge, USA 
Sortase A Kind gift of Gijsbert Grotenbreg, 
Singapore, Singapore 
T4 DNA Ligase New England Biolabs,  
Frankfurt am Main, Germany 
TMB substrate Biolegend, London, UK 
XbaI New England Biolabs, 
Frankfurt am Main, Germany 
 
2.9 Kits 
Cytofix/Cytoperm™ BD Biosciences, Heidelberg, 
Germany 
Endo-free Maxiprep Large Scale Plasmid 
Isolation Kit 
Qiagen, Hilden, Germany 
Miniprep Small Scale Plasmid Isolation Kit Qiagen, Hilden, Germany 
Mouse interleukin-2 (IL-2) ELISA Kit BD Bioscience, Heidelberg, 
Germany 
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NucleoSpin® Gel and PCR Clean-up Kit Macherey-Nagel, Düren, Germany 
PeqGOLD Plasmid Miniprep Kit Peqlab, Erlangen, Germany 
 
2.10 Lipids 
α-Galactosylceramide (α-GalCer/KRN7000) Avanti Polar Lipids, Alabaster, USA 
Galactosyl-α1-2-galactosylceramide 
(α-GalGalCer) 




Axiovert 25 Microscope Carl Zeiss, Jena, Germany 
Centrifuge Varifuge 3.0 R Heraeus, Hanau, Germany 
Centrifuge Varifuge 20 RS Heraeus, Hanau, Germany 
Chemidoc™ XRS System Bio-Rad Laboratories, München, 
Germany 
Dispenser Multipette® Plus Eppendorf, Hamburg, Germany 
Flex Station Multiplate Reader Molecular Devices, Biberach and 
der Riß, Germany 
Flow cytometer FACS Verse BD Biosciences, Heidelberg, 
Germany 
Flow cytometer & Cell Sorter FACSAriaII BD Biosciences, Heidelberg, 
Germany 
Freezer -20° C Liebherr, Bieberach an der Riß, 
Germany 
Freezer -80° C Panasonic, Hamburg, Germany 
Gel developing system GelDoc Bio-Rad Laboratories, München, 
Germany 
Gel developing system Alpha Imager Alpha-Innotec, Kasendorf, Germany 
Gel electrophoresis chamber Owl D2 Thermo Scientific, Schwerte, 
Germany 
Horizontal shaker Unihood Uniequip, Planegg, Germany 
Ice machine Ziegra, Isernhagen, Germany 
   Materials   
  - 42 - 
Incubator BBD6220 Heraeus, Hanau, Germany 
Laminar flow hood Herasafe Heraeus, Hanau, Germany 
Liquid nitrogen tank K Series Taylor Wharton, Mildstedt, Germany 
Magnetic stirrer Ikamag® RH IKA, Staufen, Germany 
Microwave R933 Sharp, Hamburg, Germany 
Micro scale CP124-OCE Sartorius AG, Göttingen, Germany 
Multi channel pipet Gilson, Villiers le Bel, France 
Pipet Boy Integra, Ratingen, Germany 
Power pack P25 Biometra, Göttingen, Germany 
Refrigerator 4° C Liebherr, Bieberach an der Riß, 
Germany 
Roller mixer Srt6d Bibby Scientific Ltd, Staffordshire, 
UK 
Roller mixer RS-TR05 Carl Roth, Karlsruhe, Germany 
Single channel pipets Research Plus Eppendorf, Hamburg, Germany 
Sonication water bath 2510 Branson, Dietzenbach, Germany 
Sprout mini centrifuge Biozym, Hessisch Olendorf, 
Germany 
Table top centrifuge Biofuge fresco Heraeus, Hanau, Germany 
Table top centrifue Biofuge pico Heraeus, Hanau, Germany 
Table top centrifuge Labofuge 400 Heraeus, Hanau, Germany 
Thermal cycler Bio-Rad MyCycler Bio-Rad, München, Germany 
Thermal cycler 2720 Applied Biosystems, Darmstadt, 
Germany 
Thermal cycler T3000 Biometra, Göttingen, Deutschland 
Vacuum pump Laboport KNF, Freiburg, Germany 
Vortex Vortexgenie 2 Scientific Industries, Schwerte, 
Germany 
Water bath SW22 Julabo, Seelbach, Germany 
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2.12  Plasmids and DNA constructs 
pcDNA3.1(+) empty Life Technologies, Darmstadt, 
Germany 
pcDNA3.1_mβ2m_mCD1d_TEV Genecust, Dudelange, Luxembourg 
pcDNA3.1_hβ2m_mCD1d_TEV Genecust, Dudelange, Luxembourg 
pcDNA3.1_hβ2m_mCD1d_TEV(GGGS)3 generated in lab 
pcDNA3.1_mβ2m_sol_mCD1d Genecust, Dudelange, Luxembourg 
pcDNA3.1_hβ2m_sol_mCD1d Genecust, Dudelange, Luxembourg 
mCD1d-Fc Kind gift of Dr. Michael Brenner, 
Boston, USA 
mCD1d-TEV-CT Kind gift of Dr. Michael Brenner, 
Boston, USA 
pcep4_LPETG_mCD1d(GGGS)0 Kind gift of Dr. Gijsbert Grotenbreg, 
Singapore, Singapore 
pcep4_LPETG_mCD1d(GGGS)1 Kind gift of Dr. Gijsbert Grotenbreg, 
Singapore, Singapore 
pcep4_LPETG_mCD1d(GGGS)2 Kind gift of Dr. Gijsbert Grotenbreg, 
Singapore, Singapore 
pcDNA3.1_LPETG_mCD1d(GGGS)0 generated through mutagenesis 
pcDNA3.1_LPETG_mCD1d(GGGS)1 generated through mutagenesis 
pcDNA3.1_LPETG_mCD1d(GGGS)2 generated through mutagenesis 
 
2.13 Software 
Adobe Illustrator Adobe Systems GmbH, München, 
Germany 
BD FACSuite BD Biosciences, Heidelberg, 
Germany 
BD FACS Diva BD Biosciences, Heidelberg, 
Germany 
FlowJo FlowJo LLC, Ashland, USA 
GraphPad Prism GraphPad Software, Inc., La Jolla, 
USA 
Image Lab Bio-Rad Laboratories, München, 
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Germany 
Microsoft Excel Microsoft, Redmond, USA 
Microsoft Word Microsoft, Redmond, USA 
SnapGene software GSL Biotech LLC; snapgene.com 
SoftMax Pro Molecular Devices, Biberach an der 
Riß, Germany 
2.14 Primers 
Table 2: Primer Sequences 
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3 Methods 
3.1 Molecular Biological Methods 
3.1.1 Polymerase Incomplete Primer Extension Polymerase Chain Reaction (PIPE 
PCR) 
A PIPE PCR is a type of mutagenesis PCR that allows the substitution of DNA 
sequences without requiring multiple PCRs or subsequent cloning steps, such as 
multi-enzymatic restriction digest and ligation. Primers, which contain a short binding 
sequence flanking the desired insertion or substitution site, and extensions 
complementary to each other, are used for the PCR. The PCR product is a linearized 
DNA sequence, including the required substitution (Figure 6).  
Subsequently, the PCR product is incubated with DpnI restriction endonuclease 
(see 3.1.3), which only digests methylated DNA, i.e. DNA previously isolated from 
bacteria expressing Dam methylase, such as E. coli, but not the PCR product. This 
strongly reduces the amount of remaining original template. 5 µl of the PCR product 
were then transformed into chemically competent Top10 E. coli (3.1.5), where the 
linearized PCR products are circularized through intracellular ligation.  
 
Figure 6: Schematic Depiction of the hβ2m_mCD1d_TEV(GGGS)3 PIPE Substitution 
PCR.  
Primers including sequences complementary to each other flank the region 
chosen for substitution. The PCR results in the linearized plasmid, containing 
the substituted sequences introduced by the primers. By using an enzyme that 
leaves blunt ends, the linearized plasmid can be re-circularized by intracellular 
ligation during bacterial transformation. Adapted f rom Klock and Lesley; 2009.92 
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DNA amplification and modification was performed using Pfu Ultra II Fusion DNA 
Polymerase and the appropriate PIPE mutagenesis primers (Table 2). The reaction 
was set up according to table 3. 
Table 3: Composition of a PIPE-PCR Reaction 
Reagent Composition per reaction Volume (Vol) per reaction 
10 x Pfu Ultra II Reaction 
Buffer 
1 x 5 µl 
dNTP Mix 25 mM each 5 µl 
fwd Primer 10 µM 1 µl 
rev Primer 10 µM 1 µl 
Pfu Ultra II Fusion DNA 
Polymerase 
1 µl 1 µl 
Template 100 ng 1 µl 
HPLC H2O ad 50 µl 36 µl 
total Vol 50 µl 50 µl 
 
Table 4: Reaction Conditions for PIPE-PCR1 
Step Process Temperature Time 
1 Initial Denaturation 95° C 3 min 
2 Denaturation 95° C 20 s 
3 Annealing 70° C 30 s 
4 Elongation 72° C 4 min 
5 Final Elongation 72° C 10 min 
6 Storage 4° C ∞ 
 
3.1.2 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to visualize PCR products and separate DNA 
fragments by size. Depending on the size of the expected DNA fragments, gels with 
a concentration of 0.7 - 2 % agarose were used. The appropriate amount of agarose 
was dissolved in 1 x TAE buffer by boiling in a microwave, and after cooling briefly, 
ethidium bromide was added (final concentration of 0.25 µg/ml). Once the gels had 
                                            
1
 Steps 2-3 were repeated 25 times. 
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set, the PCR samples or restriction digest products were resuspended with the 
appropriate amount of 10 x DNA loading dye and 10-25 µl of the product were loaded 
onto the gels. Electrophoresis was performed at 140-160 V.  
DNA fragments required for further assays such as ligation or sequencing were cut 
from the agarose gel using a scalpel and transferred to a 1.5 ml reaction tube. The 
DNA was excised from the agarose using the Macherey-Nagel Nucleospin Gel and 
PCR Clean-up kit according to the manufacturer’s protocol.  
3.1.3 Restriction Digest 
DNA can be cleaved by specific restriction endonucleases at palindromic DNA 
sequences of 4-8 base pairs, so-called restriction sites. DNA fragments cleaved by 
the same restriction enzyme can be ligated to generate new DNA sequences. 
Digestion was performed according to tables 5 and 6.  
Table 5: Restriction Digest of Plasmid DNA 
10 x Buffer 5 µl 
Restriction 
Enzymes 
1 µl each 
Plasmid DNA 0.1-1 µg 
if required, 1 x 
BSA solution  
5 µl 
HPLC H2O  ad 50 µl 
 
Table 6: Restriction Digest of PCR Products 
10 x Buffer 5 µl 
Restriction 
Enzymes 
1 µl each 
PCR Product 20 µl 
if required, 1 x 
BSA solution  
5 µl 
HPLC H2O ad 50 µl 
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As needed, one or two restriction endonucleases were used per digest. The reaction 
was incubated at 37° C for 1-2 h. One half of the reaction was loaded onto an 
agarose gel for electrophoresis, the other half was stored at -20° C. DNA fragments 
required for further analysis were excised from the agarose gel and purified using the 
Macherey-Nagel Nucleospin Gel and PCR Clean-up kit according to manufacturer’s 
protocol. 
KpnI and XbaI were used for sub-cloning of the hβ2m_mCD1d_TEV, 
mβ2m_mCD1d_TEV, hβ2m_mCD1d_TEV(GGGS)3, hβ2m_sol_mCD1d and 
mβ2m_sol_mCD1d constructs into pcDNA3.1. 
For sub-cloning of pcep4_LPETG_mCD1d(GGGS)0-2 into pcDNA3.1, NheI and 
BamHI restriction endonucleases were used.  
3.1.4 Ligation 
DNA fragments restricted by the same restriction endonuclease can be joined 
between their 5’ phosphate and 3’ hydroxy groups by T4 DNA ligase. Normally, an 
average molar ratio of 3:1 of insert to plasmid vector is used for a ligation reaction. 
The required volumes were calculated based on the concentration and size of the 
DNA fragments. 2 µl of 10 x T4 DNA ligase buffer and 1 µl of T4 DNA ligase were 
added to the DNA fragments and the reaction was filled up to a final volume of 20 µl 
using HPLC grade water. The reaction was incubated over night at 16° C and 
transformed into chemically competent E. coli the following day. Alternatively, the 
reaction was incubated for 3 h at room temperature (RT) and then transformed.  
3.1.5 Bacterial Transformation of Chemically Competent E. coli Strains 
Top10 or DH5α chemically competent E. coli were thawed on ice. 10-20 µl of the 
ligation or 100 ng to 1 µg of empty plasmid were added to 50 µl of E. coli and mixed 
by careful snipping. The cells were kept on ice for 30 min and mixed gently every 
10 min. After a 30 s heat shock in a water-bath at 42° C, the cells were kept on ice 
for an additional 2 min before being plated onto multiple LB-Agar plates (with 
100 µg/ml ampicillin) at different volumes (normally 10 µl, 20 µl, and 30 µl per 
transformation and plate). The plates were incubated at 37° C over night and 
screened for colonies the following day.  
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3.1.6 DNA Isolation from Bacterial Cells 
Bacterial colonies grown over night on LB-Agar plates with ampicillin were picked 
using sterile pipette tips and transferred to round bottom 15 ml reaction tubes 
containing 5 ml of LB Medium supplemented with 100 µg/ml ampicillin. After shaking 
at 37° C at 250 rpm in a horizontal shaker for 12-16 h, 2 ml of the bacterial 
suspension were transferred to 2 ml reaction tubes and bacterial cells were pelleted. 
The remaining cell suspension was stored at 4° C. DNA was extracted from the cells 
using either Miniprep Small Scale Plasmid DNA Isolation Kits from Qiagen or 
PeqLab, according to the manufacturer’s protocol. To ensure that the correct plasmid 
was isolated, the DNA was analyzed by restriction digest and subsequent agarose 
gel electrophoresis. If the DNA fragments detected on the gel corresponded to the 
expected sizes, the plasmid was further analyzed by Sanger sequencing. Once the 
correct sequence was confirmed, 100 µl of the cell suspension for small scale DNA 
isolation were transferred to an Erlenmeyer flask containing 200 ml LB Medium with 
100 µg/ml ampicillin and shaken at 37° C at 250 rpm for 12-16 h. Large scale DNA 
islolation was performed using Qiagen’s Maxiprep Endotoxin Free Large Scale DNA 
Isolation Kit according to the manufacturer’s protocol.  
3.1.7 TEV Protease Digest 
TEV protease is a cysteine protease isolated from the tobacco etch virus. Due to its 
high cleavage sequence specificity, it is commonly used in molecular biology for the 
cleavage of recombinant proteins.  
Cells transfected with mCD1d_TEV or WT_mCD1d were treated with Brefeldin A in 
DMEM complete (1 µg/ml final concentration) to limit the turnover of CD1d. After 
incubation for 3 h at 37° C, 5 % CO2 and 85 % humidity, the cells were trypsinized, 
transferred to 15 ml reaction tubes, washed once with DMEM complete and spun 
down at 330 × g for 5 min at RT before washing once with PBS. The cells were then 
resuspended in TEV protease reaction mix, which was set up as follows described in 
table 7. 
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Table 7: Reaction Conditions for TEV-Mediated Cleavage of CD1d 
 AcTEV ProTEV 
20 x Reaction Buffer 15 µl 10 µl 
100 mM DTT 3 µl 2 µl 
TEV Protease 10-40 U 40 U 
HPLC H2O ad 300 µl ad 200 µl 
 
AcTEV protease from Invitrogen and ProTEV protease from Promega were tested 
and compared. The reaction was incubated at 30° C for 1-1.5 h. Cells were incubated 
in DMEM complete, 1 x HBSS or 1 x TEV reaction buffer without active enzyme as 
controls. Following centrifugation at 330 × g for 5 min at RT, the supernatants were 
collected and frozen at -20° C for subsequent mCD1d ELISA (3.3.2). The cells were 
washed twice in cold FACS buffer, centrifuged and prepared for FACS staining 
(3.3.1).  
3.1.8 Sortase A (SrtA) Digest 
Sortase A is a transpeptidase originally isolated from Staphylococcus aureus. Similar 
to TEV protease, it recognizes and cleaves a specific peptide motif.  
Cells transfected with LPETG_mCD1d or WT_mCD1d were trypsinized, split into two 
1.5 ml reaction tubes, washed once with DMEM complete and centrifuged for 5 min 
at 330 × g at RT. THP-1_LPETG_hCD1d(GGGS)3 and untransfected THP-1 
suspension cells were also split into two reaction tubes, washed once and pelleted. 
Cells were then resuspended in 100 µl DMEM complete medium containing 
50 µM SrtA enzyme for half of the samples. The remaining samples were incubated 
in 100 µl DMEM complete only as controls. All samples were incubated at 37° C for 
1 h and centrifuged for 5 min at 330 × g. Supernatants were removed and stored 
at -20° C for subsequent mCD1d ELISA and the cells were washed twice in 4° C 
FACS buffer before FACS staining of mCD1d (3.3.1).  
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3.2 Cell Biological Methods 
3.2.1 Cultivation of Immortalized Cell Lines 
Human (HeLa)88 and mouse (MODE-K, L-cells)89,90 adherent cell lines were cultured 
in T75 cm2 flasks using DMEM complete (supplemented with 10 % FCS, 2 mM 
L-Gutamine and 1 % penicillin/streptomycin solution) in an incubator set to 37° C, 
5 % CO2 and 85 % humidity. The cells were passaged twice or thrice per week, at a 
confluency of 80-90 % and at a rate of 1:5 or 1:10, respectively. To this end, the cells 
were washed once with RT 1 x PBS and 3 ml of pre-warmed 1 x trypsin-EDTA 
solution were added. The cells were incubated at 37° C for 30-120 s, shaken gently 
and pipetted up and down to generate a single cell suspension. A fraction of these 
cells was either transferred to 6-well plates for experiments or transferred to a new 
T75 cm2 flask for passaging. 2 ml or 12 ml of complete DMEM were added, 
respectively, and cells were left to adhere in the incubator.  
Mouse (24.7)78 and human (THP-1)91 suspension cells were kept in RPMI complete 
(supplemented with 10 % FCS, 2 mM L-Gutamine and 1 % penicillin/streptomycin 
solution) in a standing T25 cm2 flask in an incubator at 37° C, 5 % CO2 and 85 % 
humidity. Cells were passaged thrice per week at a rate of 1:10 by pipetting up and 
down to generate a single cell suspension.  
3.2.2 Thawing of Cells Frozen for Long Term Storage 
Cells were removed from the liquid nitrogen tank and carefully thawed at 37° C in a 
water bath. They were then transferred to a 50 ml tube and 40 ml of the appropriate 
pre-warmed cell culture medium were added slowly. The cells were then centrifuged 
for 5 min at 330 × g at RT. The supernatant was removed and the cell pellet was 
resuspended in 12-15 ml of the appropriate cell culture medium, transferred to a 
T75 cm2 cell culture flask and incubated at 37° C with 5 % CO2 and a humidity of 
85 %.  
3.2.3 Freezing Cells for Long Term Storage 
Adherent cells grown to 70 – 90 % confluency in T75 cm2 cell culture flasks were 
washed once with 1 x PBS, trypsinized with 3 ml 1 x trypsin-EDTA solution and 
transferred to a 15 ml tube containing 3 ml of the appropriate medium containing 
FCS to prevent further trypsin activity. Suspension cells were grown to a 
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concentration of 1 × 107 cells/ml and washed once with fresh RPMI. Subsequently, 
the cells were counted and pelleted at 330 × g for 5 min at RT. The supernatant was 
discarded and the cells were gently resuspended in FCS containing 10 % DMSO, 
resulting in a concentration of 4-10 × 106 cells per ml. 1 ml aliquots were transferred 
to cryovials and placed in a cryobox containing isopropanol to ensure slow and 
gentle freezing of the cells. After one night at -80° C, the cells could be transferred to 
liquid nitrogen for long-term storage. 
3.2.4 Transfection of Adherent Cells Using Lipofectamine 
Cells were seeded at 5 × 105 – 7.5 × 105 cells per well into a 6-well plate in the 
appropriate medium and left to attach over night at 37° C, 5 % CO2 and 85 % 
humidity. The following day, solution A, containing the DNA and solution B, 
containing the cationic lipid transfection reagent, were pipetted into two 1.5 ml 
reaction tubes. 
Table 8: Reaction Conditions For Transfection Using Lipofectamine 
Dish Solution A Solution B Final Vol. Medium 
6-well 
100 µl DMEM w/o 
additives + 3 µg 
DNA 
100 µl DMEM w/o 




The solutions were mixed by gentle snipping and following a 5 min incubation period 
at RT, solution B was added to solution A and mixed gently. To allow for the 
formation of DNA containing liposomes, the mixture was incubated for 20 min at RT. 
In the meantime, the medium of the seeded cells, which were at 50-70 % confluency, 
was replaced with antibiotic-free medium. The DNA-lipofectamine mixture was 
pipetted drop-wise onto the dish and distributed by careful shaking. Following 
incubation over night at 37° C, 5 % CO2 and 85 % humidity, the medium of the cells 
was changed to complete medium with antibiotics and the cells were cultured until 
further analysis.  
3.2.5 Transfection of Adherent Cells Using Turbofect 
Though Turbofect is also a cationic lipid transfection reagent, the transfection 
procedure differs slightly from that used for Lipofectamine. First, the DNA was added 
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to DMEM without (w/o) additives, the previously vortexted lipofection reagent was 
added to the same tube immediately and mixed by resuspending. The mixture was 
also incubated for 20 min at RT to allow for the formation of DNA-liposome 
complexes. In the meantime, the cells’ medium was replaced by fresh DMEM 
complete. The transfection mix was then pipetted drop-wise onto the dish and 
distributed by gentle shaking. After incubation over night at 37° C, 5 % CO2 and 85 % 
humidity, the medium was changed and the cells were grown until further analysis.  
Table 9: Reaction Conditions for Transfection Using Turbofect 
Dish Vol. Turbofect [µl] Conc. DNA [µg] Final Vol. Medium 
6-well 6  4 µg/400 µl DMEM 2 ml 
 
3.2.6 Cell Killing Curve  
Plasmid DNA often contains an antibiotic-resistance cassette, rendering successfully 
and stably transfected cells less sensitive to this antibiotic. The remaining cells are 
sensitive to this antibiotic and will undergo cell death upon drug exposure, enabling 
the selection of successfully and stably transfected cells. To determine the minimal 
concentration required to induce cell death, cells were thinly seeded to 6-well plates 
(2-5 × 104 cells/well), left to adhere and incubated with the appropriate medium 
containing different concentrations of antibiotic (based on the manufacturer’s 
recommendation), including an antibiotic-free condition. The cell culture medium was 
changed every two to three days and cells were screened for viability by light 
microscopy. If the cells were still viable after one week, the antibiotic concentration 
was considered too low and the experiment was repeated with increased 
concentrations of antibiotics. If the cells were dead after two to three days of 
incubation, the antibiotic concentration was considered too high. Optimally, the cells 
treated with antibiotics would die after approximately one week, while untreated cells 
were still healthy.  
3.2.7 Generation of Stably Transfected Cell Lines 
Adherent cells were transfected with plasmid DNA on a pcDNA3.1 backbone as 
described in 3.2.4 and 3.2.5. The cells were trypsinized and one well of a 6-well-plate 
was divided onto four 10 cm dishes 24 h after the transfection. The cells were then 
incubated with the appropriate medium containing an adequate concentration of 
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Geneticin, as previously determined by a killing curve. The medium was changed 
every two to three days and cells were screened for viability. One 10 cm dish of 
untransfected cells was cultured with the same concentration of Geneticin and used 
as a reference. Once all of the untransfected cells were dead, any viable cell 
remaining was considered successfully transfected and left to grow. After 
approximately two weeks, small cell clusters had formed in the 10 cm dishes. These 
clusters were scraped off the dish using a 10 µl pipet tip and transferred to a 96-well 
plate (one cluster per well). Alternatively, the cells were trypsinized, counted and 
diluted to a concentration of 5-2.5 cells per ml of medium and seeded into a 96-well 
plate, corresponding to a concentration of one to 0.5 cells/well. Still under antibiotic 
selection, the cells were grown and transferred to larger well sizes once 80 % 
confluency was reached. At the 6-well stage, the cells were screened for the 
expression of the transfected protein by flow cytometry (3.3.1).  
3.3 Immunological Methods 
3.3.1 Staining of Cells for Flow Cytometry (FACS) 
FACS is a commonly used method to determine cellular expression of a certain 
antigen by the use of fluorophore-coupled antibodies. To analyze extracellular 
antigens, cells were washed twice with 1 ml of FACS buffer and centrifuged for 5 min 
at 4° C at 400 × g. The cells were resuspended in 100 µl FACS buffer containing the 
appropriate antibody, vortexed and incubated at 4° C in the dark for 20 min. 
Following one more washing step with 1 ml of FACS buffer and centrifugation at 
400 × g for 5 min at 4° C, the cells were resuspended in 300 µl of FACS buffer and 
analyzed using a BD FACSVerse flow cytometer. For additional staining of 
intracellular antigens, such as secreted CD1d, cells were washed after extracellular 
staining and resuspended in 250 µl Cytofix™ solution for 20 min at 4° C in the dark 
for fixation. Then, the cells were washed twice with 1 ml 1 x Perm/Wash™ solution 
for permeabilization and incubated in 100 µl Perm/Wash™ solution containing the 
appropriate quantity of antibody for 30 min at 4° C in the dark. The cells were then 
washed once with 1 x Perm/Wash™ solution and resuspended in 300 µl FACS buffer 
for flow cytometric analysis. 
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3.3.2 mCD1d Enzyme Linked Immunosorbent Assay (ELISA) 
Sandwich-ELISA is a common method to detect soluble proteins in cell culture 
supernatants or serum. Samples are normally measured in triplicates and the 
standard curve is pipetted in duplicates. First, the appropriate amount of wells of a 
96-well ELISA plate were coated with 100 µl of 10 µg/ml mCD1d 19G11 capture 
antibody diluted with blocking solution (PBS + 10 % FCS) and incubated over night at 
4° C. The following day, the plate was washed thrice with ELISA washing solution 
(PBS + 0.05 % Tween) and blocked for 1 h at RT with 200 µl/well blocking solution to 
prevent nonspecific protein binding. In the meantime, the samples to be analyzed 
were diluted 1:2 to 1:10 in blocking solution. After washing the plate thrice, 100 µl of 
the diluted samples were pipetted onto the plate in triplicates. The standard curve 
was pipetted beginning with 200 µl of a 2 ng/ml top standard solution of biotinylated 
mCD1d monomer in blocking solution and serially diluting the top standard down to 
0.03 ng/ml. Blocking solution was used as blank. Following a 2 h incubation, during 
which the soluble mCD1d proteins in the supernatant attached to the coating 
antibody, the plate was washed thrice and 100 µl of a 10 µg/ml solution of 
biotinylated 1B1 mCD1d antibody in blocking solution were pipetted into the wells 
previously containing the samples. Since the mCD1d monomer is already 
biotinylated, these wells were filled with 100 µl blocking solution to prevent drying and 
excess biotinylation. After 1 h of incubation, during which the biotinylated antibody 
binds to the mCD1d protein, the plate was washed five times and 100 µl of a 1:2500 
dilution of Avidin HRP in blocking solution was added to each well, including the 
standard curve wells. The plate was incubated for 25 min at RT and washed seven 
times with 30 s incubation between each washing step. 100 µl/well of TMB substrate 
were added/well and the plate was incubated in the dark for a maximum of 20 min. 
TMB solution is a substrate for the HPR bound to avidin and therefore acts as an 
indicator for the amount of protein present per well. With increasing protein 
concentration, the TMB substrate changes from a clear solution to a dark blue color. 
To stop the reaction, 50 µl of 1 N HCl solution were added to each well, turning the 
indicator yellow, and the extinction was measured at 450 nm using a FlexStation.  
   Methods   
  - 56 - 
3.3.3 mIL-2 ELISA  
Based on the same principle as the mCD1d ELISA, mIL-2 can be detected via 
sandwich-ELISA. For this purpose, the mIL-2 ELISA kit from BD Biosciences was 
used according to the manufacturer’s protocol.  
3.3.4 Antigen Presentation Assay 
CD1d presents lipid antigens to CD1d-restricted NKT cells. By co-culturing 
CD1d-expressing cells with an iNKT cell hybridoma (24.7) and investigating the 
supernatants after 24 h of co-culture for NKT-cell derived IL-2, it is possible to detect 
activation of the NKT hybridoma cells.  
To this end, cells transfected with mCD1d constructs in 6-well plates on the previous 
day were seeded into 96-well plates at a concentration of 5 × 104 cells/well, and left 
to adhere at 37° C with 5 % CO2 and 85 % humidity for at least six hours. In the 
meantime, 1 µg α-galactosylceramide (α-GalCer) and α-GalGalCer were diluted in 
500 µl of DMEM, sonicated for 10 min in a sonication water bath and then diluted to 
solutions with concentrations of 10 ng/ml, 20 ng/ml, 50 ng/ml and 100 ng/ml of lipid. 
The attached cells were washed once with DMEM complete and 100 µl of each lipid 
solution were added per well in triplicates and incubated over night for processing 
and loading onto CD1d. Three wells of each line of transfected cells were left without 
lipids. The next day, the cells were washed thrice with DMEM complete and 1 × 105 
24.7 cells were added to each well in a total volume of 200 µl. 24.7 cells were also 
seeded into three wells alone as negative controls, just as three wells of HeLa cells 
transfected with one of each constructs were cultured alone. After 24 h, the plate was 
briefly centrifuged to settle the cells and 100 µl of the supernatants were removed 
and stored at -20° C for subsequent IL-2 ELISA.  
3.3.5 Statistical Analysis 
Graphs were generated and analyzed using the unpaired Student’s t-test or, in case 
of multiple comparisons, one- or two-way ANOVA followed by Bonferroni’s post hoc 
analysis using GraphPad Prism software (version 5.0 for Windows; GraphPad 
Software, LaJolla, USA). P values ≤ 0.05 were considered significant and indicated 
as p ≤ 0.05 (*), p ≤ 0.01 (**) or p ≤ 0.001 (***).  
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4 Results 
4.1 Expression of Secreted and TEV Protease-Cleavable mCD1d  
CD1d, an atypical MHC class I molecule, which is expressed by a wide range of cells 
presents lipid antigens to NKT cells.24 Lipids are bound by CD1d during its transport 
through secretory and endolysosomal compartments of the cell and are presented at 
the cell surface. The origin and molecular nature of CD1d-associated lipid antigens 
has been researched extensively, but only a limited number of such antigens has 
been identified to date, let alone the complete spectrum of CD1d-associated lipids. 
The analysis of the CD1d lipidome is technically difficult, because detergents are 
necessary to isolate CD1d from the membrane and these cause the dissociation of 
the bound lipids. To avoid this, genetically engineered secreted CD1d constructs 
were generated recently.60–62,67,78,93 Secreted CD1d constructs lack the TMD and the 
cytoplasmic tail of CD1d and are therefore released into the cell culture medium after 
passage through the ER and Golgi apparatus.60–62 However, these constructs do not 
undergo endolysosomal trafficking and thus do not allow the investigation of lipids 
which associate with CD1d during its passage through these compartments. To avoid 
such limitations, a cell surface cleavable CD1d construct was recently engineered by 
Brenner and coworkers.60 In contrast to secreted CD1d, this construct undergoes 
endolysosomal trafficking, as it has an intact cytoplasmic tail and TMD, and was 
designed to allow for TEV-mediated enzymatic release of CD1d at the cell surface 
(see 1.5 and Figure 6, Figure 7).60 Surprisingly, however, the respective construct 
showed little TEV protease-mediated cleavage, thus limiting MS-based studies.60 
First analyses using this construct nevertheless demonstrated that CD1d may bind a 
wide range of lipids in vitro, which is consistent with MS-based analyses of lipids 
associated with secreted CD1d.12,60,78 
Two constructs were received from the laboratory of Dr. Michael Brenner (Brigham 
and Women’s Hospital, Harvard Medical School, Boston, MA, USA): A secreted 
(mCD1d-Fc) and a TEV-cleavable (mCD1d-TEV-CT) version of mCD1d. Both 
constructs have previously been published.60,78 The soluble mCD1d-Fc construct was 
generated as a single-chain construct with hβ2m covalently linked to the N-terminus 
of mCD1d by a glycine-serine (Gly-Ser) spacer. The transmembrane domain and 
cytoplasmic tail of mCD1d were substituted by the Fc portion of murine IgG2a and 
covalently linked to the extracellular domain by another Gly-Ser spacer.78 The cell 
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surface-cleavable construct had hβ2m covalently linked to the N-terminus of full 
length mCD1d by a Gly-Ser spacer and contained two TEV cleavage sites inserted 
just N-terminal of the transmembrane domain and C-terminal of the α3 domain of 
CD1d (Figure 7).60 Under physiological conditions, β2m non-covalently associates 
with the CD1d heavy chain in the ER.44,48 It has been shown that the association with 
β2m is important for glycosidase processing of CD1d in the Golgi apparatus and that 
CD1d heavy chains which traffic without β2m show an immature glycosylation pattern 
at the cell surface.94 As β2m expression may limit the formation of heterodimers upon 
overexpression of CD1d, covalent linkage to CD1d was applied in the constructs 
investigated here.  
Based on the publication by Muindi and colleagues, it appeared that the 
mCD1d-TEV-CT cell surface cleavable construct underwent spontaneous cleavage 
rather than enzyme-mediated shedding, since significant concentrations of CD1d 
could be detected in the supernatant of cells incubated with TEV buffer in the 
absence of active TEV enzyme.60 We therefore modified the sequence provided by 
Dr. Brenner’s laboratory by substituting one of two TEV cleavage sites with a 
Strep-tag ii for protein purification (hβ2m_mCD1d_TEV). The secreted mCD1d-Fc 
construct was also modified by adding an 8 × His tag and Strep-tag ii to mCD1d 
C-terminally, replacing the Fc portion of murine IgG2a (hβ2m_sol_mCD1d). 
Additionally, to avoid possible side effects from the association of human β2m with 
mouse CD1d, secreted and cell surface cleavable single chain mβ2m_mCD1d 
constructs were generated (mβ2m_sol_mCD1d and mβ2m_mCD1d_TEV) (Figure 7).  
To determine whether the species of β2m associated with mCD1d influences 
construct expression in a mouse small intestinal epithelial cell line (MODE-K)90, cells 
were transfected with each construct and analyzed by flow cytometry. Cells 
transfected with secreted CD1d were treated with Brefeldin A for three hours prior to 
flow cytometric analysis. Additionally, supernatants (SN) were assayed for CD1d via 
ELISA 24 h after transfection, to analyze the secretion of the secreted CD1d 
constructs and possible spontaneous shedding of the cell surface-cleavable 
constructs.  
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Figure 7: Schematic overview of mCD1d constructs 
The highest expression rate among the mCD1d constructs was recorded for 
hβ2m_mCD1d_TEV (20 %), followed by mβ2m_mCD1d_TEV (15 %) and 
hβ2m_sol_mCD1d (12 %). mCD1d-Fc had the lowest expression rate in accordance 
with it being the largest construct due to the C-terminal Fc sequence (5 %) (Figure 7, 
Figure 8). These observations correlated with CD1d expression per cell, as 
determined by the mean fluorescence intensity (MFI) of CD1d expressing cells 
(Figure 8). 
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Figure 8: Comparison of the Expression of Different Genetically Modified mCD1d 
Constructs in MODE-K cells 
(A) Relative number of cells expressing CD1d, given as a percentage of live 
cells 24 h after lipofection of the indicated mCD1d constructs into MODE-K cells. 
Cells transfected with secreted CD1d constructs were treated with Brefeldin A 
for three hours prior to analysis. (B) Mean fluorescence intensity (MFI) of CD1d 
in the subset of CD1d-expressing MODE-K cells treated as described in (A) . (C) 
Mean mCD1d levels in the supernatants (SN) of MODE-K cells treated as 
described in (A) (measured in triplicates). ELISA results in (C) were not 
normalized to CD1d expression (A, B) . This experiment was performed once, 
analyzing 2 × 105 cells per construct. 
While results could not be normalized to cellular CD1d expression, quantification of 
mCD1d spontaneously released into the supernatant of transfected MODE-K cells 
demonstrated that CD1d was only secreted into the medium by MODE-K cells 
transfected with hβ2m_mCD1d_TEV and hβ2m_sol_mCD1d (Figure 8). Though this 
observation indicated spontaneous cleavage of the hβ2m_mCD1d_TEV fusion 
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protein, we decided to proceed with hβ2m_mCD1d_TEV and hβ2m_sol_mCD1d, 
based on their expression rates.  
4.2 TEV Protease for Enzymatic Release of CD1d 
For the establishment of a TEV cleavage protocol, we decided to generate cells 
stably expressing TEV-cleavable CD1d. To this end, we decided to transfect L cells, 
a mouse fibroblast cell line89, with hβ2m_mCD1d_TEV (L-TEV-cells). L cells, which 
are stably transfected with WT mCD1d, were used as control since WT CD1d is not 
sensitive to TEV-mediated proteolytic cleavage (L-WT-cells). 
L-TEV-cells cells and L-WT-cells cells were incubated for three hours with Brefeldin 
A95, an antibiotic that interferes with anterograde trafficking of proteins from the ER to 
the Golgi, to arrest trafficking of newly synthesized CD1d to the cell surface. We used 
the manufacturer’s protocol for AcTEV protease (Invitrogen) as a reference for our 
experimental setup, estimating the concentration of cleavable protein and using 
AcTEV at a concentration four times higher than required (1 µl). The transfected cells 
were trypsinized, washed, and incubated for 1 h at 30° C, according to the 
manufacturer’s recommendation for optimal TEV activity. Either DMEM complete or 
AcTEV buffer, a Tris-based buffer provided with TEV protease, were used as 
reaction buffers - with or without DTT and with or without active enzyme.  
Noteworthy, only 20 % of cells stably transduced with hβ2m_mCD1d_TEV showed 
detectable levels of CD1d at the cell surface, whereas more than 90 % of the L-WT-
cells cells were positive for CD1d. While the molecular basis for these observations 
was not investigated, previous studies using mouse embryonic stem cells and CHO 
cells expressing recombinant proteins have demonstrated transcriptional silencing by 
epigenetic modification of the CMV promoter, as well as progressive loss of gene 
copies during cell culture.96,97 It is therefore possible that such mechanisms may 
have contributed to limited hβ2m_mCD1d_TEV expression in our experiments. 
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Figure 9: TEV Protease Fails to Cleave hβ2m_mCD1d_TEV, While TEV Buffer Affects 
Cell Viability 
Cells stably transfected with hβ2m_mCD1d_TEV (L-TEV-cells) or with WT 
mCD1d (L-WT- cells) were incubated in DMEM or TEV buffer with or without DTT 
and active enzyme as indicated. (A) Representative histograms showing the 
viability of cells 24 h after transfection (B) Representative dot plots depicting the 
frequency of CD1d low (CD1d l o) and high (CD1dhi) expressing live cells as 
determined by flow cytometry. This experiment was performed once in 
duplicates.  
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Regardless of limited CD1d expression, flow cytometric analysis of L cells stably 
transduced with hβ2m_mCD1d_TEV or WT_mCD1d demonstrated that the use of 
TEV buffer, even in the absence of TEV protease, significantly affected cell viability 
(Figure 9). Furthermore, no evidence of TEV-protease-mediated cleavage of 
hβ2m_mCD1d_TEV was detected, as indicated by unaltered cell surface expression 
of CD1d in all conditions (Figure 9).  
The secretion of mCD1d into the SN was analyzed by ELISA. Treatment of stably 
hβ2m_mCD1d_TEV-transfected L cells with TEV buffer plus AcTEV (+ DTT) resulted 
in the highest concentration of mCD1d in the culture supernatant (0.5 ng/ml), 
followed by DMEM with DTT and AcTEV, as well as AcTEV buffer plus DTT 
(0.26 ng/ml). However, analysis of the supernatants of L-WT-cells cells, which 
express WT CD1d without a TEV cleavage site and thus should not release mCD1d 
into the SN, revealed mCD1d levels of up to 3 ng/ml after exposure to TEV buffer 
and only 0.3 ng/ml after exposure to DMEM (Figure 10). These data, together with 
flow cytometric data showing decreased viability upon AcTEV buffer exposure, 
suggest that treatment of eukaryotic cells with AcTEV buffer results in cell lysis and 
thereby uncontrolled release of mCD1d into the supernatant. 
 
Figure 10: mCD1d ELISA of Supernatants of Mouse Fibroblast Cells Stably 
Transfected with hβ2m_mCD1d_TEV or WT mCD1d 
Mean mCD1d concentrations in the supernatant of L cells stably transfected with 
hβ2m_mCD1d_TEV (L-TEV-cells) or with WT mCD1d (L–WT-cells) upon the 
indicated treatment, as determined by ELISA. mCD1d levels were slightly 
increased in L cells treated with AcTEV + TEV buffer, but even more so in 
Ld cells, which should not respond to TEV digestion. The experiment was 
performed once and mean values of triplicates are shown. 
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4.3 Investigation of different buffer systems and alternative TEV proteases 
The previous experiment with stably transfected L-TEV-cells and L-WT-cells led to 
the conclusion that the use of TEV buffer was detrimental to cell integrity and should 
thus be avoided. However, the experiment also demonstrated that the use of DMEM 
as reaction buffer for TEV cleavage of hβ2m_mCD1d_TEV did not allow for 
detectable CD1d release. DMEM complete is supplemented with fetal calf serum 
(FCS), which contains a range of proteins and organic compounds. While FCS helps 
maintain cell viability during incubation, it may contain substances which are 
inhibitory to TEV protease. Thus, we investigated potential alternative buffers 
compatible with TEV protease. HBSS is commonly used in the isolation of primary 
cells from tissues but does not contain FCS and was therefore considered an 
adequate substitute for DMEM with fewer components that might inhibit TEV activity. 
Additionally, to ensure that the concentration of TEV protease was sufficient for 
CD1d cleavage, the TEV protease concentration was doubled in subsequent 
experiments. Furthermore, TEV protease from a different distributor, ProTEV 
(Promega), was used alongside the previously used AcTEV (Invitrogen) protease. 
Given that HeLa cells, a cell line generated from human cervical cancer cells88, 
exhibited increased CD1d expression after transfection with hβ2m_mCD1d_TEV, 
subsequent experiments were performed 24 h after transient transfection of HeLa 
cells instead of L cells. Cells were treated with Brefeldin A for three hours and then 
either incubated in HBSS or the TEV buffer provided by the respective TEV 
manufacturer, with and without active protease. One sample in DMEM only was 
added as a control. As for the previous experiments, cleavage was performed at 
30° C for 1 h according to manufacturer’s protocols.  
Flow cytometric analysis revealed that the cells were more sensitive to the Invitrogen 
TEV buffer than they were to the Promega TEV buffer or HBSS, as indicated by a 
population shift in the FSC/SSC scatter (Figure 11 A, upper panel). More importantly, 
however, TEV protease-mediated proteolytic release of CD1d at the cell surface was 
not observed in any of the conditions (Figure 11 A lower panel and B).  
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Figure 11: Alternative Buffer Systems and TEV Proteases for Enzymatic Release of 
CD1d 
(A) Flow cytometric analysis of HeLa cells  transiently transfected with 
hβ2m_mCD1d-TEV treated with AcTEV or ProTEV protease, either wi th the 
appropriate TEV buffer or HBSS. DMEM and HBSS alone were used as negative 
controls. Upper panel: HeLa cells were more sensitive to Invitrogen TEV buffer, 
as indicated shifts in the FSC scatter (top panels). Lower panel: Relative 
frequency of CD1d+ cells among the FSC/SSC population gated as shown in the 
top panel. (B) mCD1d cell surface expression per cell , gated on CD1d+ cells, as 
determined by mean fluorescence intensity (MFI). The experiment was 
performed once.  
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4.4 Glycine-Serine Spacers Do Not Promote TEV Protease Dependent 
Cleavage of hβ2m_mCD1d_TEV 
Based on the design of the hβ2m_mCD1d_TEV construct with the TEV recognition 
sequence close to the plasma membrane, we speculated that the lack of detectable 
surface shedding may be caused by inaccessibility of the cleavage site for TEV 
protease. 
We therefore decided to insert three Gly-Ser spacers ((GGGS)3) between the TMD 
and the TEV cleavage site, to enhance accessibility. A similar hCD1d construct 
containing a Sortase A transpeptidase (SrtA) cleavage site (LPETG) separated from 
the TMD by three GGGS spacers (LPETG-hCD1d(GGGS)3), had previously been 
shown to be cleavable by Gijsbert Grotenbreg and colleagues (National University of 
Singapore, Singapore, Singapore) (unpublished data).  
Instead of classic mutagenesis techniques, we performed PIPE mutagenesis, which 
enables the substitution of a DNA sequence with a mutagenized, longer sequence in 
just one PCR (see 3.1.1). PCR products were directly transformed into chemically 
competent E. coli and construct sequences were verified by Sanger sequencing. 
HeLa cells were then transiently transfected with the mutagenized construct 
(hβ2m_mCD1d_TEV(GGGS)3) and TEV protease cleavage was investigated as 
previously described using AcTEV and ProTEV protease with the appropriate buffers.  
Flow cytometric analysis of the relative frequency of live CD1d+ cells and also of the 
MFI of these CD1d expressing cells did not reveal any proteolytic release of CD1d 
from the cell surface (Figure 12 A, B).  
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Figure 12: Glycine-Serine Spacers Do Not Promote TEV Protease-Mediated Cleavage 
of CD1d. 
HeLa cells were transfected with hβ2m_mCD1d_TEV(GGGS)3 and analyzed 24 h 
after transfection. (A) Representative flow cytometry dot plots showing the cell 
surface expression of hβ2m_mCD1d_TEV(GGGS)3 before and after treatment as 
indicated. (B) Quantif ication of the relative percentage of live CD1d expressing 
cells (left) and CD1d expression per cell gated on CD1d+ cells (MFI, right). 
Median and range of two individual experiments performed in duplicates are 
shown. (C) mCD1d ELISA from SN of cells treated as described in A. Median 
and range of two individual experiments performed in duplicates are shown.  
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ELISA results revealed that cells treated with AcTEV TEV buffer and AcTEV 
protease released more mCD1d into the supernatant than cells treated with AcTEV 
TEV buffer or ProTEV TEV buffer alone or ProTEV TEV buffer plus ProTEV 
protease. However, the concentration of mCD1d secreted by cells treated under the 
same conditions with DMEM only was in the same range (Figure 12 C). Thus, despite 
the introduction of glycine-serine spacers, no TEV-mediated cleavage of mCD1d 
from the cell surface could be detected.  
In conclusion, TEV protease-based strategies did not allow for proteolytic release of 
CD1d at the cell surface. We therefore decided to pursue a different strategy for 
proteolytic CD1d cleavage.  
4.5 Sortase A for proteolytic release of CD1d 
As an alternative for the hβ2m_mCD1d_TEV construct, we investigated mCD1d 
constructs containing an LPETG sequence in the extracellular juxtamembrane 
domain of CD1d, which serves as a recognition site for Staphylococcus aureus 
sortase A (SrtA), a bacterial transpeptidase that cleaves the threonine-glycine bond 
within the LPETG sequence.85 Constructs were engineered to contain none, one or 
two Gly-Ser spacers between the transmembrane domain and the LPETG cleavage 
site (pcep4_LPETG_mCD1d(GGGS)0-2), which itself was positioned between the 
TMD and the α3 domain of mCD1d. Unlike the TEV constructs, the LPETG_mCD1d 
constructs were not covalently linked to β2m, as we observed that cellular β2m 
expression and non-covalent binding to CD1d are not rate-limiting for CD1d 
expression (data not shown). 
As done previously for hβ2m_mCD1d_TEV, HeLa cells were transiently transfected 
using lipofection and analyzed 24 h after transfection. The cells were trypsinized and 
half of the cells of each well were incubated for 1 h at 37° C in DMEM with or without 
50 µM SrtA enzyme. The cells were then analyzed by flow cytometry and ELISA for 
mCD1d. THP-1 cells, a human leukemic monocyte cell line91 stably transfected with a 
human CD1d construct containing three Gly-Ser spacers 
(pcep4_LPETG_hCD1d(GGGS)3) were previously shown to be amenable to sortase-
mediated CD1d cleavage (personal communication, Gijsbert Grotenbreg, National 
University of Singapore, Singapore, Singapore) and were used as a positive control 
for SrtA activity. 
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Figure 13: SrtA Digest of HeLa Cells Transfected with LPETG_mCD1d(GGGS)0-2 or 
THP 1 Cells Stably Transfected with LPETG_hCD1d_(GGGS)3. 
HeLa cells were transfected with LPETG_mCD1d(GGGS)0-2 and subjected to 
SrtA digest 24 h after transfection. (A) Dot plots (duplicate samples) showing 
SrtA dependent reduction of CD1d expression on live cells representative of five 
individual experiments. Cleavage efficiency increases with the number of GGGS 
spacers while baseline expression decreases. (B) Quantification of the relative 
number of CD1d expressing cells. Mean ± SEM of f ive individual experiments 
performed in duplicates is shown (Student’s t -test; * p < 0.05, *** p < 0.01). 
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Cell surface expression of the constructs as determined in the absence of SrtA 
treatment decreased with the number of Gly-Ser spacers, whereas cleavage 
efficiency as determined in the presence of SrtA increased ( A, B). While a SrtA-
dependent reduction of CD1d expression was barely detectable for the GGGS0 
construct, SrtA-induced loss of CD1d cell surface expression was observed for 25 % 
and 33 % of cells expressing the GGGS1 and GGGS2 constructs, respectively (). 
These results were confirmed by the analysis of the concentration of CD1d in the cell 
culture SN by ELISA (Figure 14). While an increase of CD1d in the SN was detected 
for all three constructs, the relative increase was substantially higher for the GGGS1 
and GGGS2 constructs compared to the GGGS0 construct. Up to 10 ng/ml of mCD1d 
were measured in the supernatant. This corresponds to 1 ng of mCD1d derived from 
5 × 105 cells, which is considered sufficient for MS analysis.  
However, baseline release of CD1d in the absence of SrtA treatment also increased 
with each additional Gly-Ser spacer, suggesting that these spacers enhanced the 
accessibility of the CD1d protein for SrtA but also contributed to structural instability 
associated with spontaneous CD1d cleavage (Figure 14).  
 
Figure 14: mCD1d ELISA of HeLa Cells Transfected with LPETG_mCD1d(GGGS)0-2 
after SrtA Digest 
HeLa cells were transfected with LPETG_mCD1d(GGGS) 0-2 and subjected to 
SrtA digest 24 h after transfection. CD1d concentrations in SN taken from cells 
after SrtA digest as determined by ELISA (median values with range  from two 
individual experiments performed in triplicates).  
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4.6 Increased LPETG_CD1d Expression Through Use of an Alternative 
Plasmid Backbone 
Unlike hβ2m_mCD1d_TEV, LPETG_mCD1d(GGGS)1 and GGGS2 could be cleaved 
from the cell surface of HeLa cells upon digestion with SrtA at considerable rates, 
resulting in the release of 1 ng of CD1d from 5 × 105 cells. However, the transfection 
rate of the LPETG_mCD1d constructs was quite low, compared to the rates achieved 
using hβ2m_mCD1d_TEV in HeLa cells. We speculated that this may relate to the 
fact that these constructs were on different vector backbones (pcep4 and pcDNA3.1, 
respectively). Thus, we sub-cloned the LPETG_mCD1d constructs into pcDNA3.1 
and investigated the transfection rates in HeLa cells after transient lipofection.  
Using pcDNA3.1 instead of pcep4 increased the expression rate of all three 
LPETG_mCD1d constructs by two- to three-fold, reaching close to 20 % transfected 
cells for GGGS0 and GGGS1. As observed previously, GGGS2 showed the lowest cell 
surface expression (Figure 15).  
 
 
Figure 15: Flow Cytometric Analysis of the Expression of LPETG_mCD1d(GGGS)0-2 
using pcep4 and pcDNA3.1 Vector Backbones. 
HeLa cells were transfected with LPETG_mCD1d(GGGS)0-2 on either vector 
backbone in the same experiment and analyzed for CD1d cell surface expression 
by flow cytometry. Representative dot plots show the increase in CD1d 
expressing cells when using a pcDNA3.1 vector backbone.   
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When compared with WT mCD1d on a pcDNA3.1 backbone, 
LPETG_mCD1d(GGGS)0 had nearly the same surface expression (Figure 15). Again, 
baseline CD1d cell surface expression negatively correlated with the number of 
glycine-serine spacers. Conversely, SrtA digestion became more efficient. While the 
GGGS0 construct was not cleaved at all, the number of GGGS1 expressing cells was 
reduced by approximately 20 % and GGGS2 expressing cells by close to 50 % 
(Figure 16 A). Likewise, CD1d expression per cell, as determined by MFI, showed 
the same trend (Figure 16 B).  
While the reduction in the relative frequency of CD1d expressing cells was greater for 
LPETG_mCD1d(GGGS)2 compared to LPETG_mCD1d(GGGS)1, the MFI of CD1d
+ 
cells was equally reduced by approximately 50 % for both constructs (Figure 16 B). 
Considering that LPETG_mCD1d(GGGS)1 shows a higher cell surface expression 
compared to LPETG_mCD1d(GGGS)2, which was confirmed by the frequency of 
CD1d-positive cells and the MFI, protein yields from both constructs were anticipated 
to be similar, even with a lower cleavage efficiency of LPETG_mCD1d(GGGS)1. This 
was indeed confirmed by ELISA, revealing mCD1d levels of more than 2 ng in the 
SN of 5 × 105 HeLa cells transfected with either LPETG_mCD1d(GGGS)2 or 
LPETG_mCD1d(GGGS)1 and treated with SrtA (Figure 16 C). Again, however, 
increasing the number of spacers led to spontaneous cleavage of LPETG_mCD1d 
(Figure 16 C). 
Even though the digestion efficiency increased with the number of spacers, this 
positive effect was partially compensated by the observation that baseline expression 
and protein stability appeared to be negatively influenced by addition of GGGS 
spacers. Since the protein yield after SrtA treatment did not differ between the 
GGGS1 and GGGS2 constructs and since the LPETG_mCD1d(GGGS)2 construct 
underwent significant spontaneous cleavage, we considered 
pcDNA3.1_LPETG_mCD1d(GGGS)1 the most suitable construct for proteolytic 
cleavage of cell surface CD1d and subsequent MS analysis of bound lipids. 
However, one essential factor still needed to be investigated: The capacity of any of 
the constructs tested to present antigen to CD1d-restricted T cells. 
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Figure 16: SrtA Digest of HeLa cells Transfected with 
pcDNA_LPETG_mCD1d(GGGS)0-2. 
HeLa cells were transfected with pcDNA3.1_LPETG_mCD1d(GGGS)0-2 and used 
for SrtA digest 24 h after transfection. (A) Dot plots depicting the relative 
expression rate of CD1d and histograms representing the expression per cell of 
the CD1d+ subset of cells. Cells show decreasing expression rates of mCD1d, 
but increasing cleavage efficiency with increasing spacer number.  (B) 
Quantification of the relative percentage of CD1d-positive cells (left) and CD1d 
expression per cell gated on CD1d+ cells(MFI) with and without active enzyme 
(right). (C) Release of CD1d into the SN of cells incubated with or without SrtA, 
as determined by ELISA. A shows individual plots and B and C show the mean of 
duplicate values from one experiment.  
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4.7 CD1d-Dependent Antigen Presentation Is Affected by Gly-Ser Spacers 
CD1d-mediated antigen presentation is a complex process, which depends on CD1d 
trafficking, lipid loading and exchange as well as appropriate alignment of CD1d with 
the TCR. We therefore investigated whether the addition of Gly-Ser spacers or the 
SrtA motif itself altered the ability of CD1d to load and present lipid antigens. 
HeLa cells were transfected with WT and LPETG_mCD1d. 24 hours after 
transfection, the expression of mCD1d was determined by flow cytometry and cells 
were seeded into 96-well plates, in which they were co-cultured with the 24.7 iNKT 
cell hybridoma.78 NKT cells recognize natural cellular lipids in the context of CD1d, 
which is associated with their activation and has been termed autoreactivity. 
Transfected HeLa cells were first co-cultured in the absence of exogenous lipids to 
test for the loading and presentation of endogenous lipids. Additionally, transfected 
HeLa cells were incubated with increasing concentrations of 
α-galactosylceramide (αGalCer) or galactosyl-α1-2-galactosylceramide 
(αGalGalCer), prior to addition of the 24.7 cells, to test for the loading and 
presentation of exogenous lipids. αGalCer is a potent antigen for iNKT cells and is 
therefore often used as a positive control for the induction of iNKT cell activation.13,78 
αGalGalCer needs to be processed to αGalCer by lysosomal enzymes to induce 
CD1d-mediated activation of iNKT cells.65 By using these two lipids, we could not 
only investigate the capacity of the mCD1d constructs to present antigen, but could 
also determine if they exhibited unimpaired endolysosomal trafficking. Activation of 
the iNKT cell hybridomas was assessed by secretion of mIL-2.  
For both αGalCer and αGalGalCer, the concentration of mIL-2 in the SN of the co-
cultured cells increased in a dose-dependent manner for all mCD1d constructs 
tested. WT_mCD1d induced the strongest activation upon presentation of αGalCer, 
while the GGGS0 construct was associated with only slightly less iNKT cell activation 
(Figure 17 A). Addition of GGGS spacers reduced the ability of CD1d to activate 
iNKT cells, which was particularly evident for the LPETG_mCD1d(GGGS)2 construct 
(Figure 17 A).  
αGalGalCer induced slightly stronger NKT cell responses compared to αGalCer, 
indicating sufficient trafficking of all mCD1d constructs. Using αGalGalCer, 
WT_CD1d, LPETG_mCD1d(GGGS)0, and LPETG_mCD1d(GGGS)1 showed largely 
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comparable iNKT cell activation, while LPETG-mCD1d(GGGS)2 again induced a 
considerably weaker iNKT cell response (Figure 17 A). 
 
 
Figure 17: Antigen Presentation by LPETG_mCD1d(GGGS)0-2 Expressing HeLa Cells. 
HeLa cells were transfected with the indicated mCD1d constructs . 24 h after 
transfection, the cells were either incubated over night with the implied 
concentrations of αGalCer or αGalGalCer or cultured without the addition of 
exogenous lipids. The following day, the cel ls were washed extensively and 1 
× 105 24.7 cells were added per well. Supernatants of the co-cultures were taken 
after 24 h. (A) mIL-2 ELISA of SN taken from HeLa cells previously incubated 
with αGalCer or αGalGalCer after 24 h of co-culture with 24.7 cells. The 
secretion of IL-2 represents the response of 24.7 cells to exogenous lipids 
presented by CD1d. (Two-way ANOVA with Bonferroni post-hoc analysis; * p < 
0.05, *** p < 0.01; GGGS0-2 compared with mCD1d WT) (B) mIL-2 ELISA of SN 
taken from the co-culture of HeLa and 24.7 cells without previous addition of 
exogenous antigen. The secretion of mIL-2 represents the response of 24.7 cells 
to endogenous antigen presentation (One-way ANOVA with Bonferroni post-hoc 
analysis; ** p ≤ 0.01, *** p ≤ 0.001). (Mean values with SEM, all experiments 
were performed in triplicates.) 
Similar to the data described for presentation of exogenous antigens, the addition of 
GGGS spacers to mCD1d reduced the response to the presentation of endogenous 
antigen. Surprisingly, the NKT hybridomas’ response to WT_mCD1d was nearly 
twice as strong compared to the construct only containing the LPETG sequence 
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(LPETG_mCD1d(GGGS)0). A comparison of the three LPETG_mCD1d constructs 
revealed that the addition of one GGGS spacer reduced iNKT cell activation only 
minimally, while the addition of two spacers again decreased it by approximately 
50 % (Figure 17 B).  
Of note, results on antigen presentation were not corrected for decreased cell 
surface expression of CD1d as observed for LPETG_mCD1d(GGGS)1 and 
LPETG_mCD1d(GGGS)2. We therefore conclude that at least the mild alterations in 
antigen presentation observed for LPETG_mCD1d(GGGS)1 were likely related to 
slightly decreased cell surface expression. 
Altogether, our data demonstrate that LPETG_mCD1d(GGGS)1 is an engineered 
CD1d molecule amenable to SrtA-mediated proteolytic release at the cell surface 
with minor effects on CD1d expression, trafficking, and antigen loading, as well as 
presentation. We thus report the establishment of a novel, enzymatically cleavable 
CD1d construct, which, alongside secreted CD1d, may provide the basis for the first 
comprehensive analysis of CD1d-associated lipid antigens in vitro and ex vivo.  
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5 Discussion 
CD1d restricted, lipid-reactive NKT cells have been shown to play a crucial role in a 
range of immune responses, including antimicrobial immunity, tumor immunity, and 
inflammatory disorders, such as IBD or asthma.12 Capable of rapidly secreting large 
amounts of various cytokines and chemokines, NKT cells can influence most cells of 
the innate and adaptive immune system and thus direct both pro- and anti-
inflammatory immune reactions.11 However, our knowledge of the antigens involved 
in CD1d-mediated activation of NKT cells is limited, which is largely due to technical 
limitations associated with the loss of CD1d-bound lipids during extraction and 
purification of CD1d. We therefore aimed to develop CD1d proteins which allow for 
enzymatic cleavage of CD1d at the cell surface lipids, while showing little impact on 
subcellular trafficking as well as antigen loading and presentation by CD1d. Such 
engineered proteins could serve as the basis for mass spectrometric analysis of 
CD1d-associated lipids and will provide new opportunities to identify these in vitro 
and in vivo. A better understanding of the CD1d lipidome may provide helpful 
information for the development of strategies towards therapeutic targeting of lipid 
antigen presentation in NKT cell-mediated diseases. 
5.1 Hβ2m_mCD1d_TEV Protease Does Not Allow for Proteolytic Release of 
Cell Surface CD1d 
During the search for methods to facilitate the investigation of CD1d-associated 
lipids, different genetically modified CD1d constructs were developed recently. 
Experiments with these constructs have provided critical information on the 
importance of different cellular compartments for lipid loading and modification and 
also on a small number of lipid antigens capable of activating NKT cells.36,52,60–62,67,78 
However, most of the constructs amenable to CD1d collection and MS analysis do 
not undergo trafficking through the endolysosomal system but are restricted to 
secretory compartments. As an exception, Muindi et al.60 described a mCD1d 
construct with an intact transmembrane and cytoplasmic domain and largely 
unaltered intracellular trafficking of CD1d, which was designed to be cleaved at the 
cell surface using exogenously added TEV protease. However, the authors observed 
similar release of CD1d in the presence or absence of TEV protease, suggesting 
spontaneous cleavage of the engineered CD1d molecule upon exposure to TEV 
buffer.60 In an attempt to solve these issues, we first optimized the construct 
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sequence by removing one TEV cleavage site and substituting it with a Strep-tag ii 
for subsequent protein purification. In a second construct we replaced hβ2m with 
mβ2m, so that β2m and CD1d were derived from the same species 
(hβ2m_mCD1d_TEV and mβ2m_mCD1d_TEV). A secreted mCD1d construct lacking 
the TMD and C-terminus of CD1d originally published by Gumperz and colleagues 
(mCD1d-Fc) and also used by Muindi et al. was also modified.60,78 Instead of the Fc 
region of mouse IgG2a, a Strep-tag ii and an 8 x His tag were added to the 
C-terminus of the α3 domain of CD1d. A secreted CD1d construct associated with 
mβ2m instead of hβ2m was also generated (hβ2m_sol_mCD1d, mβ2m_sol_mCD1d) 
(Figure 7). Interestingly, transfection of these constructs into mouse intestinal 
epithelial cells (MODE-K) revealed that the modified constructs associated with hβ2m 
(hβ2m_mCD1d_TEV and hβ2m_sol_mCD1d) had a higher relative expression than 
those associated with mβ2m (Figure 8). Due to high sequence homology of both β2m 
and class I receptor α-chains in humans and mice, mouse β2m can associate with 
human MHC class I (major histocompatibility complex I) receptors and human β2m 
can dimerize with mouse MHC class I.98–101 Studies have shown that heterodimers of 
hβ2m with human or mouse MHC I are both more stable than heterodimers formed 
with mβ2m, independent of species origin of MHC class I.
99,100 The molecular basis 
for these observations remains unclear, but our results indicate that the same 
principle holds true for β2m-mCD1d heterodimers.  
Hβ2m_mCD1d_TEV was well expressed in different mouse and human cell lines 
(MODE-K, L cells, HeLa cells), but we were not able to detect TEV-mediated release 
of cell surface CD1d in any of the experiments performed (Figure 9-Figure 12). 
Neither a different commercial source of TEV protease, nor an increase in the 
concentration of TEV protease or the addition of Brefeldin A to prevent replenishment 
with newly synthesized CD1d led to detectable TEV-dependent CD1d cleavage.  
We also demonstrated that AcTEV buffer was detrimental to the cells, which may be 
related to the moderately basic pH of the buffer (Tris-HCl at pH 8.0) and the lack of 
proteins, electrolytes and nutrients which are normally contained in cell-culture 
medium. The TEV buffer provided by Promega was less detrimental, most likely 
because it consisted of 50 mM HEPES at neutral pH 7 (Figure 11). DMEM or HBSS 
provided a better environment for the cells, but contain sodium chloride, which may 
have adverse effects on TEV protease activity.102 Additionally, DMEM contains fetal 
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calf serum, which is a natural product and thus contains a range of organic 
substances103 that might affect TEV protease.  
Furthermore, we considered that the lack of TEV-mediated CD1d shedding may be 
caused by inaccessibility of the cleavage site located in the juxtamembrane portion of 
the CD1d protein between the α3 domain and the TMD. We therefore generated a 
construct with three GGGS spacers inserted between the TMD and the cleavage site 
(hβ2m_mCD1d_TEV(GGGS)3). However, increasing the distance between the 
plasma membrane and the TEV recognition motif did not improve cleavage (Figure 
12). Thus, we concluded that TEV-mediated shedding of the CD1d extracellular 
domain from the surface of eukaryotic cells cannot be achieved with the current 
constructs and further confirm recent data,60 suggesting that the previously observed 
release of TEV-CD1d represents spontaneous rather than TEV-induced release of 
CD1d, possibly as a consequence of impaired cell viability in TEV buffer. 
5.2 Sortase A-Mediated Release of Cell Surface CD1d  
 As an alternative for the TEV-cleavable CD1d construct, we began working with 
LPETG_mCD1d. LPETG is an amino acid motif recognized by the S. aureus SrtA 
transpeptidase, which cleaves the threonine-glycine bond in this recognition 
sequence. Similar to the TEV-cleavable construct, the LPETG constructs had the 
SrtA cleavage site inserted between the TMD and α3 domain of mCD1d, but were not 
covalently linked to β2m. These constructs were either designed with none, one or 
two GGGS spacers just C-terminal of the cleavage site, thereby increasing the 
distance between the LPETG motif and the TMD.  
All of the constructs were detectable at the cell surface of transfected HeLa cells, 
with cell surface expression inversely correlating with the number of Gly-Ser spacers 
added. Conversely, the efficiency of SrtA-mediated release of cell surface 
LPETG_mCD1d improved with the addition of each GGGS spacer (Fig. 13). Because 
the relative expression of the LPETG_mCD1d constructs in HeLa cells was lower 
than the expression previously seen for hβ2m_mCD1d_TEV, we sub-cloned the 
constructs from their pcep4 vector backbone into pcDNA3.1. Changing the vector 
backbone to pcDNA3.1 increased the expression rate by two to three-fold compared 
to pcep4, even though both plasmids use the same CMV promotor/enhancer element 
for transcription initiation (Figure 15). This effect is likely due to the smaller plasmid 
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size of pcDNA3.1, which is nearly half the size of pcep4 and reflects the observation 
that vector size negatively affects transfection rates and promotor activity.104 
We therefore continued working with the LPETG_mCD1d(GGGS)0-2 constructs on a 
pcDNA3.1 plasmid backbone. With a higher expression of the constructs, the protein 
yield from cleavage experiments also increased, resulting in as much as 2 ng of 
mCD1d released into the SN of 5 × 105 HeLa cells transfected with 
LPETG_mCD1d(GGGS)1 and LPETG_mCD1d(GGGS)2 after incubation with SrtA 
(Figure 16). However, we also observed an increase in non-enzymatic, spontaneous 
shedding of the LPETG_mCD1d constructs proportional to the spacer number. Gly-
Ser spacers are a commonly used tool in the generation of fusion-proteins. Due to 
their small size and lack of complex side-chains, glycine and serine make up flexible 
linker elements, which have also been detected in naturally occurring proteins.105,106 
Another study investigating the properties of naturally occurring linker peptides stated 
that the majority of linkers consisted of more complex amino acids and were 
therefore more rigid. According to their analysis, the average length of a naturally 
occurring linker peptide is 10 ± 5.8 amino acids.107 Glycine-rich linkers are 
considered independent units that do not affect the functions of the linked domains, 
in part because glycine does not readily form α-helices.105 A study with poly-glycine 
linkers of different lengths (Gn) added to the protein Rop demonstrated that an 
increase in linker length did not affect the protein’s folding or capability to bind RNA, 
but a longer linker was associated with decreased protein stability in tests with 
thermal and chemical denaturation.108 Though the linker peptides used in our 
constructs lie within the average length of naturally occurring linker peptides, it is 
possible that the high flexibility combined with the linker length destabilizes the 
protein, especially in the LPETG_mCD1d(GGGS)2 construct. Nevertheless, it is 
noteworthy that while no spontaneous shedding was detected for the 
LPETG_mCD1d(GGGS)0 construct, SrtA-induced release was also only detected at 
very low levels. It thus appears that the addition of the GGGS spacer(s) is required 
for SrtA binding to, and processing of, CD1d and at the same time leads to moderate 
spontaneous release of LPETG-CD1d.  
To investigate whether the sortase motif or the Gly-Ser spacer(s) affect 
CD1d-restricted antigen presentation, HeLa cells transfected with WT_mCD1d and 
the LPETG_mCD1d constructs were either directly co-cultured with iNKT hybridoma 
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cells or incubated with exogenous lipid antigens before co-culture with iNKT cells. 
Independent of the presented antigen, the ability to activate iNKT cells in a CD1d-
restricted manner negatively correlated with the presence and number of Gly-Ser 
spacers. While LEPTG_mCD1d(GGGS)0 and LEPTG_mCD1d(GGGS)1 exhibited 
only mild alterations in the presentation of endogenous and exogenous lipid antigens, 
possibly as a consequence of slightly decreased cell surface expression of these 
constructs, LEPTG_mCD1d(GGGS)2 exhibited significant defects in the presentation 
of self- and non-self-antigens (Figure 17). Given that two CD1d ligands with distinct 
subcellular processing and loading requirements yielded similar results for 
LEPTG_mCD1d(GGGS)2, alterations in antigen presentation are unlikely to result 
from altered endolysosomal trafficking (Figure 17).  
A more likely explanation for the obtained results is an altered positioning of the 
CD1d lipid binding groove relative to the iNKT TCR, induced by the addition of the 
LPETG cleavage site and/or the Gly-Ser spacer(s). The interaction of lipid-loaded 
CD1d with the NKT-TCR is different from the interaction of the TCR with MHC class I. 
Unlike the diagonal positioning, which is observed for the interaction between the 
TCR and MHC class I, the iNKT TCR docks over the F’ pocket of CD1d, 
approximately parallel to the long axis of the CD1d antigen binding groove. The iNKT 
TCR hereby spans areas of the α1 and α2 domains of CD1d, with complementarity 
determining region (CDR) 2β and CDR3α playing an important role in TCR-CD1d-
antigen interaction.109–111 The affinity of the interaction is not just dependent on the 
positioning of the TCR relative to CD1d, but also on the antigen presented. In 
crystallization studies of the synergy between the Vα14 TCR and CD1d either loaded 
with the exogenous antigen αGalCer or the endogenous antigen iGb3, a much lower 
affinity for the endogenous antigen was measured.111,112 Considering the complexity 
of CD1d-TCR interactions, it seems conceivable that a slight alteration in the 
positioning of CD1d relative to the TCR, due to the insertion of a cleavage site or a 
flexible linker, could be disruptive for CD1d-TCR interactions.  
Taken together, we present an engineered CD1d protein, LPETG_mCD1d(GGGS)1, 
which exhibited substantial SrtA-mediated release at the cell surface and yields 
amounts of CD1d predicted to be sufficient for MS-based analysis. Further, this 
construct showed limited spontaneous release in the absence of SrtA and exhibited 
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only minor alterations in CD1d expression and antigen loading as well as 
presentation. 
5.3 Conclusion and Outlook 
Here, we present novel CD1d proteins engineered to contain the recognition site for 
SrtA to allow for SrtA-mediated enzymatic cleavage of CD1d at the cell surface. 
These constructs shall provide the basis for future, systematic analyses of 
CD1d-associated lipids in vivo and in vitro. 
To avoid interference with the folding and antigen binding of CD1d, the SrtA 
recognition site was integrated into the juxtamembrane region of CD1d, in between 
the TMD and the extracellular α3 domain. Insertion of the SrtA recognition motif into 
CD1d had only minor effects on protein expression and antigen presentation. 
However, the positioning of the LPETG motif in close proximity to the plasma 
membrane did not allow for sufficient enzyme-mediated CD1d cleavage at the cell 
surface, most likely due to inaccessibility of the cleavage site. We therefore 
integrated Gly-Ser spacers between the TMD and the sortase motif and observed 
that the addition of one or more Gly-Ser spacers promoted the access of SrtA to the 
LPETG motif and allowed for cleavage of CD1d at the cell surface. The concentration 
of CD1d released upon SrtA treatment is predicted to be sufficient for lipidomics-
based characterization of CD1d-associated lipids. However, addition of the spacers 
also promoted spontaneous, non-enzymatic release of CD1d. Further, addition of the 
Gly-Ser spacer(s) negatively affected CD1d-restricted antigen presentation, 
presumably resulting from spontaneous CD1d cleavage as well as altered 
interactions with the NKT TCR due to increased flexibility of the engineered CD1d 
protein. Considering these observations, adding one GGGS spacer to the SrtA motif 
served as an optimal compromise allowing for sufficient SrtA-mediated CD1d 
cleavage, while limiting spontaneous shedding and alterations in CD1d-resticted 
antigen presentation.  
In future studies, SrtA-cleavable CD1d proteins as engineered in this work will be 
used to investigate the spectrum of CD1d-associated lipids in vitro and in vivo. 
Comparison of CD1d-associated lipids isolated from cells transfected with 
LPETG_mCD1d and a secreted form of CD1d will provide important information on 
differences between lipids loaded while trafficking along the secretory pathway and 
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lipids loaded within the endolysosomal compartments. Also, treatment of 
LPETG_CD1d-transfected cells with stimuli resembling inflammatory conditions or 
using cells representative of different developmental stages of cancer113, may allow 
the investigation of potentially disease-associated changes in the CD1d lipid 
repertoire. By means of hydrodynamic injection114 or transgenic expression, it may 
further be possible to express genetically engineered CD1d in vivo to directly 
investigate differences between CD1d-associated lipids under healthy and 
inflammatory conditions.  
Thus, LPETG_mCD1d may provide the basis for novel strategies to identify CD1d-
restricted antigens involved in protective and pathogenic NKT cell responses in vivo. 
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6 Summary 
CD1d is an atypical MHC class I molecule which is expressed by a range of 
professional and non-professional antigen presenting cells (APCs). Unlike classical 
MHC receptors, CD1d does not present peptide antigens to conventional T cells but 
presents lipid antigens to natural killer T (NKT) cells. NKT cells are involved in a 
multitude of immune responses and play a key role in the development of the human 
inflammatory bowel disease ulcerative colitis (UC).  
The search for CD1d-restricted lipid antigens involved in the activation of intestinal 
NKT cells is therefore critical for a better understanding of the mechanisms 
responsible for the initiation of NKT cell-dependent intestinal inflammation in UC. 
However, the identification of lipids associated with CD1d is laborious and technically 
challenging, as isolation of CD1d from the plasma membrane through classical 
isolation methods has previously been associated with inevitable dissociation of 
CD1d-bound lipids. Genetically engineered CD1d proteins lacking the 
transmembrane domain (TMD) and cytoplasmic domain are secreted and thus do not 
require extraction from the plasma membrane. However, these proteins undergo 
incomplete subcellular trafficking and fail to survey endolysosomal compartments, 
thus providing limited information on the range of CD1d-associated lipids.  
Here, we present genetically engineered CD1d proteins, which undergo unimpaired 
trafficking through secretory and endolysosomal compartments and can be 
enzymatically cleaved at the cell surface of eukaryotic cells. To this end, CD1d was 
engineered to contain amino acid motifs in its extracellular juxtamembrane region, 
which are recognized by TEV protease (hβ2m_mCD1d_TEV) or Sortase A (SrtA) 
transpeptidase (LPETG_mCD1d). While TEV protease-dependent enzymatic 
cleavage of hβ2m_mCD1d_TEV could not be achieved, SrtA allowed for proteolytic 
release of CD1d from the plasma membrane. However, SrtA-dependent release of 
CD1d was only possible after the addition of glycine-serine spacers between the 
TMD and the SrtA recognition motif. This likely promoted access of SrtA to its 
cleavage site but also facilitated spontaneous release of CD1d in the absence of 
SrtA. CD1d engineered to contain only one glycine-serine spacer, however, allowed 
for substantial SrtA-dependent cleavage with limited spontaneous release of CD1d 
and only minor alterations in CD1d expression and antigen loading as well as 
presentation.  
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In conclusion, we present CD1d proteins amenable to proteolytic release at the cell 
surface, which may provide the basis for future analyses of the repertoire of CD1d-
associated lipids in health and disease.  
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7 Zusammenfassung  
CD1d ist ein atypisches MHC I Molekül, das von einer Reihe professioneller, sowie 
nicht professioneller Antigen präsentierender Zellen exprimiert wird. Anders als 
klassische MHC I Moleküle präsentiert CD1d keine Peptid-Antigene an 
konventionelle T Zellen, sondern Lipid-Antigene an Natürliche Killer T (NKT) Zellen. 
NKT Zellen sind an einer Vielzahl von Immunreaktionen beteiligt und spielen eine 
zentrale Rolle in der Pathogenese der Colitis ulcerosa.  
Um ein besseres Verständnis für die NKT Zell-abhängigen Mechanismen intestinaler 
Entzündung in der Colitis ulcerosa zu erlangen, ist es von zentraler Bedeutung mehr 
über die Lipid-Antigene zu erfahren, die zur Aktivierung intestinaler NKT Zellen 
beitragen. Die Identifikation CD1d-assoziierter Lipid-Antigene ist jedoch ein technisch 
anspruchsvolles Unterfangen. Klassische, Detergenzien-abhängige 
Isolierungsmethoden für Transmembranproteine können für CD1d nicht angewandt 
werden, da diese mit einem unvermeidbaren Verlust der gebundenen Lipide 
einhergehen. Eine Lösung für diese Problematik stellen genetisch modifizierte CD1d 
Proteine dar, die aufgrund fehlender Transmembran- und cytoplasmatischen 
Domänen sezerniert werden und somit nicht aus der Plasmamembran isoliert werden 
müssen. Allerdings werden diese Moleküle lediglich durch die sekretorischen 
Kompartimente (endoplasmatisches Retikulum, Golgi-Apparat) transportiert und 
liefern somit keine Informationen zu Lipid-Antigenen, die innerhalb der 
endolysosomalen Kompartimente von CD1d gebunden werden.  
In dieser Arbeit präsentieren wir genetisch modifizierte CD1d Proteine, deren 
intrazellulärer Transport nicht beeinträchtigt ist und die durch enzymatische Spaltung 
an der Oberfläche eukaryotischer Zellen isoliert werden können. Zwei kurze Peptide, 
die als Erkennungssequenzen für TEV Protease (hβ2m_mCD1d_TEV) oder 
Sortase A Transpeptidase (LPETG_mCD1d) dienen, wurden in die extrazelluläre 
juxtamembranäre Domäne des CD1d Moleküls integriert. Während eine effiziente 
Spaltung des Proteins durch TEV Protease nicht erreicht werden konnte, ließ sich 
das Sortase-spaltbare Protein erfolgreich isolieren. Voraussetzung für eine 
erfolgreiche Spaltung war jedoch die vorherige Integration von Glycin-Serin Peptiden 
zwischen der Transmembrandomäne und der Sortase A Schnittstelle. Diese Spacer 
Peptide machten die Sortase A Schnittstelle vermutlich zugänglicher, förderten aber 
auch die Enzym-unabhängige Spaltung des Proteins. Das Einfügen eines einzelnen 
   Zusammenfassung   
  - 87 - 
Glycin-Serin Peptids resultierte in einer verbesserten Spaltbarkeit von CD1d mit 
minimaler Enzym-unabhängiger Freisetzung. Zudem wurden die Beladung und 
Präsentation von Lipid-Antigenen durch die Integration eines Glycin-Serin Peptids 
nur marginal beeinflusst.  
Zusammengefasst präsentieren wir CD1d Proteine, die in Enzym-spezifischer Weise 
an der Oberfläche eukaryotischer Zellen proteolytisch gespalten und freigesetzt 
werden können und somit die Grundlage für zukünftige Untersuchungen des CD1d-
assoziierten Lipidspektrums in vitro und in vivo bilden sollen.  
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